Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply.
The veins and arteries of the HEART.
Radiography of the vascular system of the heart muscle after injection of a contrast medium.
Devices that provide support for tubular structures that are being anastomosed or for body cavities during skin grafting.
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
The return of a sign, symptom, or disease after a remission.
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
Stents that are covered with materials that are embedded with chemicals that are gradually released into the surrounding milieu.
The circulation of blood through the CORONARY VESSELS of the HEART.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Narrowing or constriction of a coronary artery.
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion.
Use of a balloon catheter for dilation of an occluded artery. It is used in treatment of arterial occlusive diseases, including renal artery stenosis and arterial occlusions in the leg. For the specific technique of BALLOON DILATION in coronary arteries, ANGIOPLASTY, BALLOON, CORONARY is available.
Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.
Spasm of the large- or medium-sized coronary arteries.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Obstruction of flow in biological or prosthetic vascular grafts.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.
The use of ultrasound to guide minimally invasive surgical procedures such as needle ASPIRATION BIOPSY; DRAINAGE; etc. Its widest application is intravascular ultrasound imaging but it is useful also in urology and intra-abdominal conditions.
The condition of an anatomical structure's being constricted beyond normal dimensions.
The innermost layer of an artery or vein, made up of one layer of endothelial cells and supported by an internal elastic lamina.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Elements of limited time intervals, contributing to particular results or situations.
A family of percutaneous techniques that are used to manage CORONARY OCCLUSION, including standard balloon angioplasty (PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY), the placement of intracoronary STENTS, and atheroablative technologies (e.g., ATHERECTOMY; ENDARTERECTOMY; THROMBECTOMY; PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY). PTCA was the dominant form of PCI, before the widespread use of stenting.
Complete blockage of blood flow through one of the CORONARY ARTERIES, usually from CORONARY ATHEROSCLEROSIS.
High energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
Percutaneous transluminal procedure for removing atheromatous plaque from the coronary arteries. Both directional (for removing focal atheromas) and rotational (for removing concentric atheromatous plaque) atherectomy devices have been used.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Unstable isotopes of iridium that decay or disintegrate emitting radiation. Ir atoms with atomic weights 182-190, 192, and 194-198 are radioactive iridium isotopes.
The restoration of blood supply to the myocardium. (From Dorland, 28th ed)
The hospital unit in which patients with acute cardiac disorders receive intensive care.
A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.
The nonstriated involuntary muscle tissue of blood vessels.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Use or insertion of a tubular device into a duct, blood vessel, hollow organ, or body cavity for injecting or withdrawing fluids for diagnostic or therapeutic purposes. It differs from INTUBATION in that the tube here is used to restore or maintain patency in obstructions.
The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
Narrowing or stricture of any part of the CAROTID ARTERIES, most often due to atherosclerotic plaque formation. Ulcerations may form in atherosclerotic plaques and induce THROMBUS formation. Platelet or cholesterol emboli may arise from stenotic carotid lesions and induce a TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; or temporary blindness (AMAUROSIS FUGAX). (From Adams et al., Principles of Neurology, 6th ed, pp 822-3)
The degree to which BLOOD VESSELS are not blocked or obstructed.
Reconstruction or repair of a blood vessel, which includes the widening of a pathological narrowing of an artery or vein by the removal of atheromatous plaque material and/or the endothelial lining as well, or by dilatation (BALLOON ANGIOPLASTY) to compress an ATHEROMA. Except for ENDARTERECTOMY, usually these procedures are performed via catheterization as minimally invasive ENDOVASCULAR PROCEDURES.
The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.
The main artery of the thigh, a continuation of the external iliac artery.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
Biocompatible materials usually used in dental and bone implants that enhance biologic fixation, thereby increasing the bond strength between the coated material and bone, and minimize possible biological effects that may result from the implant itself.
Techniques using laser energy in combination with a balloon catheter to perform angioplasty. These procedures can take several forms including: 1, laser fiber delivering the energy while the inflated balloon centers the fiber and occludes the blood flow; 2, balloon angioplasty immediately following laser angioplasty; or 3, laser energy transmitted through angioplasty balloons that contain an internal fiber.
Pathologic deposition of calcium salts in tissues.
Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.
Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures.
The plan and delineation of prostheses in general or a specific prosthesis.
Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
The excision of the thickened, atheromatous tunica intima of a carotid artery.
Drugs used to cause dilation of the blood vessels.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Motion pictures of the passage of contrast medium through blood vessels.
An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
Coronary artery bypass surgery on a beating HEART without a CARDIOPULMONARY BYPASS (diverting the flow of blood from the heart and lungs through an oxygenator).
Endovascular procedure in which atheromatous plaque is excised by a cutting or rotating catheter. It differs from balloon and laser angioplasty procedures which enlarge vessels by dilation but frequently do not remove much plaque. If the plaque is removed by surgical excision under general anesthesia rather than by an endovascular procedure through a catheter, it is called ENDARTERECTOMY.
The vein which drains the foot and leg.
Radiography of blood vessels after injection of a contrast medium.
Formation and development of a thrombus or blood clot in the blood vessel.
Either of two large arteries originating from the abdominal aorta; they supply blood to the pelvis, abdominal wall and legs.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
A distribution in which a variable is distributed like the sum of the squares of any given independent random variable, each of which has a normal distribution with mean of zero and variance of one. The chi-square test is a statistical test based on comparison of a test statistic to a chi-square distribution. The oldest of these tests are used to detect whether two or more population distributions differ from one another.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Electropositive chemical elements characterized by ductility, malleability, luster, and conductance of heat and electricity. They can replace the hydrogen of an acid and form bases with hydroxyl radicals. (Grant & Hackh's Chemical Dictionary, 5th ed)
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
A value equal to the total volume flow divided by the cross-sectional area of the vascular bed.
The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE.
Ultrasonography applying the Doppler effect combined with real-time imaging. The real-time image is created by rapid movement of the ultrasound beam. A powerful advantage of this technique is the ability to estimate the velocity of flow from the Doppler shift frequency.
Maintenance of blood flow to an organ despite obstruction of a principal vessel. Blood flow is maintained through small vessels.
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Either of the two principal arteries on both sides of the neck that supply blood to the head and neck; each divides into two branches, the internal carotid artery and the external carotid artery.
The hollow, muscular organ that maintains the circulation of the blood.
Genetically developed small pigs for use in biomedical research. There are several strains - Yucatan miniature, Sinclair miniature, and Minnesota miniature.

Serial intravascular ultrasound analysis of the impact of lesion length on the efficacy of intracoronary gamma-irradiation for preventing recurrent in-stent restenosis. (1/1466)

BACKGROUND: The relation between lesion length and effectiveness of brachytherapy is not well studied. METHODS AND RESULTS: We compared serial (postintervention and follow-up) intravascular ultrasound findings in 66 patients with native coronary artery in-stent restenosis (ISR) who were treated with (192)Ir (15 Gy delivered 2 mm away from the radiation source). Patients were enrolled in the Washington Radiation for In-Stent Restenosis Trial (WRIST; ISR length, 10 to 47 mm; n=36) or Long WRIST (ISR length, 36 to 80 mm; n=30). External elastic membrane, stent, lumen, and intimal hyperplasia (IH; stent minus lumen) areas and source-to-target (intravascular ultrasound catheter to external elastic membrane) distances were measured. Postintervention stent areas were larger in WRIST and smaller in Long WRIST patients (P:<0.0001). At follow-up, maximum IH area significantly increased in both WRIST and Long WRIST patients (P:<0.0001 for both), but this increase was greater in Long WRIST patients (P:=0.0006). Similarly, minimum lumen cross-sectional area significantly decreased in both WRIST and Long WRIST patients (P:<0.05 and P:<0.0001, respectively), but this decrease was more pronounced in Long WRIST patients (P:=0.0567). The maximum source-to-target distance was longer in Long WRIST than in WRIST, and it correlated directly with ISR length (r=0.547, P:<0.0001). Overall, the change in minimum lumen area and the change in maximum IH area correlated with the maximum source-to-target distance (r=0.352, P:=0.0038 and r=0.523, P:<0.0001 for WRIST and Long WRIST, respectively). The variability (maximum/minimum) in IH area at follow-up also correlated with the maximum source-to-target distance (r=0.378, P:<0.0001). CONCLUSIONS: Brachytherapy may be less effective in longer ISR lesions because of the greater variability and longer source-to-target distances in diffuse ISR.  (+info)

Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. (2/1466)

BACKGROUND: Restenosis remains an important limitation of interventional cardiology. Therefore, we aimed to determine the safety and efficacy of sirolimus (a cell-cycle inhibitor)-coated BX Velocity stents. METHODS AND RESULTS: Thirty patients with angina pectoris were electively treated with 2 different formulations of sirolimus-coated stents (slow release [SR], n=15, and fast release [FR], n=15). All stents were successfully delivered, and patients were discharged without clinical complications. Independent core laboratories analyzed angiographic and 3D volumetric intravascular ultrasound data (immediately after procedure and at 4-month follow-up). Eight-month clinical follow-up was obtained for all patients. There was minimal neointimal hyperplasia in both groups (11.0+/-3.0% in the SR group and 10.4+/-3.0% in the FR group, P:=NS) by ultrasound and quantitative coronary angiography (in-stent late loss, 0.09+/-0.3 mm [SR] and -0.02+/-0.3 mm [FR]; in-lesion late loss, 0.16+/-0.3 mm [SR] and -0.1+/-0.3 mm [FR]). No in-stent or edge restenosis (diameter stenosis >or=50%) was observed. No major clinical events (stent thrombosis, repeat revascularization, myocardial infarction, or death) had occurred by 8 months. CONCLUSIONS: The implantation of sirolimus-coated BX Velocity stents is feasible and safe and elicits minimal neointimal proliferation. Additional placebo-controlled trials are required to confirm these promising results.  (+info)

Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications. (3/1466)

BACKGROUND: In the randomized Balloon Angioplasty and Anticoagulation Study (BAAS), the addition of oral anticoagulants to aspirin significantly reduced early and late events after coronary angioplasty. However, bleeding episodes were increased. The present report studied the intensity and the duration of anticoagulation as predictors of thrombotic and bleeding events. METHODS AND RESULTS: A total of 530 patients, 34% of whom received a stent, were treated with aspirin plus coumarins. Half of the patients were randomized to angiographic follow-up. The target international normalized ratio (INR) was 2.1 to 4.8 during angioplasty and 6-month follow-up. Thrombotic events were death, myocardial infarction, target lesion revascularization, and thrombotic stroke. Bleeding complications were hemorrhagic stroke, major extracranial bleeding, and false aneurysm. "Optimal" anticoagulation was defined as an INR in the target range for at least 70% of the follow-up time. There were 17 early thrombotic events (3.2%), 7 early bleeding episodes (1.3%), and 10 false aneurysms (1.9%). The incidence rate for both early thrombotic and bleeding events was lowest in patients in the target range. A total of 61 late thrombotic events occurred (11.6%). Optimal anticoagulation was an independent predictor of late thrombotic events (relative risk, 0.33; 95% CI, 0.19 to 0.57) and was associated with a 0.21 mm (95% CI, 0.17 to 0.42) larger vessel lumen at 6 months. Late bleeding episodes (1.4%) were lowest in patients in the target range. CONCLUSIONS: Coumarins started before coronary angioplasty with a target INR of 2.1 to 4.8 led to the lowest procedural event rate, without an increase in bleeding episodes. During follow-up, optimal anticoagulation was associated with a decrease in the incidence of late events by 67% and a significant improvement in 6-month angiographic outcome.  (+info)

Relation of a common methylenetetrahydrofolate reductase mutation and plasma homocysteine with intimal hyperplasia after coronary stenting. (4/1466)

BACKGROUND: Hyperhomocysteinemia has been identified as an independent risk factor for coronary artery disease. Recent studies have shown that a common mutation (nucleotide 677 C-->T) in the methylenetetrahydrofolate reductase (MTHFR) gene may contribute to mild hyperhomocysteinemia and, therefore, to the incidence of coronary artery disease. No information exists, however, regarding the association between the mutation of the MTHFR gene or plasma homocysteine levels and morphological analysis of coronary atherosclerosis using intravascular ultrasound. METHODS AND RESULTS: To examine the potential influence of MTHFR genotype and homocysteine on coronaryarteries morphologically, we screened 62 patients with 65 lesions that were treated with 93 Palmaz-Schatz stents. The plasma homocysteine levels in the patients with the TT genotype were not significantly higher than those in the patients with non-TT (CC+CT) genotypes (13.1 +/- 5.5 versus 11.5 +/- 3.1 mmol/L, P=0.16). Angiographic analysis showed that the percent diameter stenosis in the patients with the TT genotype was significantly greater than that in those with non-TT genotypes (43.7 +/- 17.8% versus 29.0 +/- 22.0%, P=0.015). Intravascular ultrasound analysis showed that the TT genotype was significantly associated with greater intimal hyperplasia area (5.70 +/- 1.94 versus 3.72 +/- 1.38 mm2, P=0.001). In multiple stepwise regression analysis, the number of the T alleles was the only independent predictor of intimal hyperplasia after intervention (r2=0.21, P=0.004). CONCLUSIONS: The homozygous mutant genotype of the MTHFR gene may increase the risk of in-stent restenosis more than does the normal homozygous or heterozygous genotype.  (+info)

Long-term effects of intracoronary beta-radiation in balloon- and stent-injured porcine coronary arteries. (5/1466)

BACKGROUND: The data on the long-term safety and efficacy of intracoronary beta-radiation in animal models are limited. METHODS AND RESULTS: A total of 30 coronary arteries in 15 swine were subjected to balloon or stent injury followed by beta-radiation from a centered 32P source (2000 cGy to 1 mm beyond lumen surface) or a sham radiation procedure. The animals received aspirin for 6 months and ticlopidine for 30 days. Five of the 10 animals subjected to radiation died (at 5 days, 7 days, 3 months [n = 2], and 4 months) as a result of layered, occlusive thrombus at the intervention site (3 stent and 2 balloon injury sites). No deaths occurred in the control group. In the surviving animals, balloon-injured and irradiated vessels showed a trend toward larger lumens than controls (2.15 +/- 0.17 versus 1.80 +/- 0.08 mm2, P=0.06) and larger external elastic lamina areas (3.32 +/- 0.21 versus 2.62 +/- 0.10 mm2, P=0.003). In the stent-injured vessels from surviving animals, lumen, neointimal, and external elastic lamina areas were 3.58 +/- 0.33, 3.16 +/- 0.35, and 8.12 +/- 0.42 mm2 for irradiated vessel segments; these values were not different from those in controls (3.21 +/- 0.15, 2.84 +/- 0.27, and 7.76 +/- 0.28 mm2, respectively). Histologically, healing was complete in most survivors, although intramural fibrin and hemorrhage were occasionally seen. CONCLUSION: In the long-term (6 month) porcine model of restenosis, the inhibition by intracoronary beta-radiotherapy of the neointimal formation that is known to be present at 1 month is not sustained. This lack of effect on neointimal formation after balloon and stent arterial injury is accompanied by subacute and late thrombosis that leads to cardiac death on a background of continuous aspirin but relatively brief ticlopidine treatment.  (+info)

Lipid peroxidation may predict restenosis after coronary balloon angioplasty. (6/1466)

The present study assessed whether lipid peroxidation in plasma might predict restenosis after coronary balloon angioplasty. A total of 87 patients, who had undergone successful coronary balloon angioplasty using standard techniques, were enrolled. Fasting blood samples before the intervention were measured for plasma levels of thiobarbituric acid reactive substances (TBARS, an indicator of lipid peroxidation). Angiography was carried out before and 15 min after angioplasty, and at follow-up (4 months after angioplasty), and evaluated using a quantitative approach. There were 23 patients with restenosis (group R) and 64 patients without restenosis (group N) after coronary balloon angioplasty. The plasma TBARS level (mean+/-SEM) of 4.3+/-0.1 micromol/L in group R was significantly higher than that of 3.2+/-0.1 micromol/L in group N (p<0.01). There were no significant differences in other parameters, including plasma lipid levels, between the 2 groups. The plasma level of TBARS positively correlated with lumen loss of the coronary artery at the time of follow-up angiography (r=0.57, p<0.01). Our results suggest that oxidative stress contributes to restenosis and indicate that an elevated plasma level of TBARS may be a reliable predictor of restenosis.  (+info)

Histopathologic evaluation of coronary artery thrombi obtained by directional coronary atherectomy in patients with restenosis-induced unstable angina pectoris. (7/1466)

The pathogenesis of unstable angina pectoris (UAP) following percutaneous transluminal coronary angioplasty (PTCA) or directional coronary atherectomy (DCA) has not been adequately investigated, so the present study aimed to determine whether thrombi are present in restenotic lesions. The study group comprised 14 patients (16 arterial branches) with angina pectoris in whom either PTCA or DCA was performed and who had developed UAP associated with restenosis, and who then underwent DCA of the restenosed lesion (R-UAP group). The control groups comprised individuals with UAP undergoing DCA with no prior history of PTCA or DCA (P-UAP group; n=29, 29 branches), patients with acute myocardial infarction (AMI group; n=34, 34 branches), and patients with stable angina pectoris (SAP group; n=31, 33 branches). The presence of thrombi was determined by light microscopy of histologic specimens. Thrombus was present in only 1 of the 16 (6.3%) branches in the R-UAP group. 21 of the 29 (72.4%) branches in the P-UAP group, and in 25 of the 34 (73.5%) in the AMI group. In the SAP group, it was detected in only 2 of the 33 (7.1%) branches. The incidence of thrombus was significantly lower in the R-UAP group than in the P-UAP group. In conclusion, the role of thrombus is limited in causing post-interventional UAP at restenosed sites.  (+info)

Intracoronary brachytherapy in the treatment of in-stent restenosis. Initial experience in Brazil. (8/1466)

Intracoronary brachytherapy using beta or gamma radiation is currently the most efficient type of therapy for preventing the recurrence of coronary in-stent restenosis. Its implementation depends on the interaction among interventionists, radiotherapists, and physicists to assure the safety and quality of the method. The authors report the pioneering experience in Brazil of the treatment of 2 patients with coronary in-stent restenosis, in whom beta radiation was used as part of the international multicenter randomized PREVENT study (Proliferation REduction with Vascular ENergy Trial). The procedures were performed rapidly and did not require significant modifications in the traditional techniques used for conventional angioplasty. Alteration in the radiological protection devices of the hemodynamic laboratory were also not required, showing that intracoronary brachytherapy using beta radiation can be incorporated into the interventional tools of cardiology in our environment.  (+info)

TY - JOUR. T1 - The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis. T2 - Insights from the e-select 64-71 (multicenter post-market surveillance) registry. AU - Abizaid, Alexandre. AU - Costa, J. Ribamar. AU - Banning, Adrian. AU - Bartorelli, Antonio L.. AU - Dzavik, Vladimir. AU - Ellis, Stephen. AU - Gao, Runlin. AU - Holmes, David R.. AU - Jeong, Muyng Ho. AU - Legrand, Victor. AU - Neumann, Franz Josef. AU - Nyakern, Maria. AU - Orlick, Amy. AU - Spaulding, Christian. AU - Worthley, Stephen. AU - Urban, Philip M.. PY - 2012/1/1. Y1 - 2012/1/1. N2 - This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. There is paucity of consistent data on DES for the treatment of ISR, ...
In 2001, when Morice et al. (1) presented the initial results of RAVEL (The Randomized Study With the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions), showing 0% angiographic restenosis 6 months after implantation of a sirolimus-eluting stent, very few people would have envisaged that more than 10 years later, there would be a need for a trial to evaluate the best treatment strategy for drug-eluting stent (DES) in-stent restenosis (ISR).. Although widespread use of DES (versus bare-metal stents [BMS]), advances in stent design, and greater operator experience have all significantly reduced the incidence of restenosis and resultant target vessel revascularization (2), a low rate of ISR continues to exist and it is not benign. Outcomes are even poorer for those with DES compared with individuals presenting with BMS-ISR (3).. There are several treatment options for DES-ISR (e.g., repeat percutaneous coronary ...
Background: Differences in restenosis pattern and timing between bare-metal stent and drug-eluting stent (DES) have been reported. However, little is known about the effect of the type of DES on restenosis pattern and timing.. Methods: From November 2002 to August 2010, 6676 consecutive patients were treated with sirolimus-eluting stent (SES: 6321 lesions), paclitaxel-eluting stent (PES: 1520 lesions), zotarolimus-eluting stent (ZES: 599 lesions), everolimus-eluting stent (EES: 924 lesions), and biolimus-eluting stent (BES: 288 lesions), and underwent midterm follow-up coronary angiography (f/u CAG) at 8 months after implantation. Of these, patients without restenosis underwent late f/u CAG at 12 months after midterm f/u. We defined early restenosis as restenosis at midterm f/u and late restenosis as restenosis at late f/u without early restenosis. Restenosis patterns were classified into two groups according to Mehran classification: focal (pattern I) and diffuse (pattern II, III, ...
The principal findings of the ISAR-DESIRE 2 study are that in cases of DES restenosis occurring within a SES: 1) the implantation of a second DES is feasible and safe; 2) a strategy of either repeat SES implantation or switch to a PES is associated with comparable anti-restenotic efficacy; and 3) the neointimal inhibition observed with repeat SES implantation is somewhat lower than expected, indicative perhaps of the existence of some degree of drug hyporesponsiveness at an individual patient level.. The widespread adoption of DES therapy coupled with an overall increase in the number of PCI procedures has generated significant absolute numbers of patients presenting with DES restenosis (2). Clinically, the treatment of these DES restenotic lesions seems to be associated with slightly higher rates of recurrent restenosis than that observed after treatment of bare-metal stent restenosis. For example, the use of DES to treat bare-metal stent restenosis has been associated with repeat TLR rates at ...
TY - JOUR. T1 - Association of Triglyceride Deposit Cardiomyovasculopathy with Drug-Eluting Stent Restenosis among Patients with Diabetes. AU - Nakano, Yusuke. AU - Suzuki, Mayu. AU - Hirano, Ken Ichi. AU - Ando, Hirohiko. AU - Takashima, Hiroaki. AU - Takahashi, Hiroshi. AU - Amano, Tetsuya. PY - 2020/8. Y1 - 2020/8. UR - http://www.scopus.com/inward/record.url?scp=85089301356&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85089301356&partnerID=8YFLogxK. U2 - 10.1001/jamanetworkopen.2020.12583. DO - 10.1001/jamanetworkopen.2020.12583. M3 - Article. C2 - 32766797. AN - SCOPUS:85089301356. VL - 3. JO - JAMA network open. JF - JAMA network open. SN - 2574-3805. IS - 8. M1 - e2012583. ER - ...
1. The patient has an in-stent restenosis of , 50% (by subjective angiographic determination of the minimal luminal diameter compared to the distal reference diameter) within a native coronary artery which has previously undergone stent placement ( 4 weeks). Lesions must meet ISR Classification I-III.. 2. The patient has a history, signs of, or laboratory studies that suggest coronary ischemia attributable to the target stenosis. The diagnosis of angina pectoris is defined by Canadian Cardiovascular Society Classification (CCS I, II, III, or IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR patients with documented silent ischemia;. 3. The study target lesion must be located in an in-stent restenotic native coronary artery measuring , 2.75mm and 3.5mm in diameter and , 15mm and 40mm in length to allow treatment with a maximum of three 18mm stents. The target lesion must have undergone coronary interventional treatment , 4 weeks previously. Patients with one or more prior ...
Drug-eluting balloon for in-stent restenosis Yin Chen, Shilian Hu, Lei Wu To the Editor: We read with interest the meta-analysis by Indermuehle A et al which reported that drug-eluting balloon (DEB) appears to show great promise for in-stent restenosis (ISR), and could reduce the risk for major adverse cardiac events (MACE) compared with plain balloon angioplasty (BA)or implantation of drug-eluting stent (DES) in the treatment of ISR (1).Coronary ISR, happened after coronary stent implantation, continued to be a major problem. The authors raised a critical concern assessing the effectiveness of DEB, and long-term outcomes were adequately discussed in the article. Actually, for the PACCOCATH (Treatment of ISR by Paclitaxel Coated PTCA Balloon) trial, the short-term outcomes were not identified in the meta- analysis (2, 3), and the subgroup analysis according to control group (BA or DES) was only adopted for late lumen loss. DEB appears to be more effective in the reduction of binary restenosis ...
In the first-in-human study, 50 patients with in-stent restenosis (following either a drug-eluting stent or bare metal stent) underwent coronary angioplasty with the Virtue balloon. The primary safety endpoint was the 30-day rate of target lesion failure-a composite of cardiac death, target vessel myocardial infarction, and clinically-driven target lesion revascularisation-and the primary performance endpoint was in-stent late lumen loss at six months.. Results. Verheye et al comment: No target lesion failures were reported through the 30-day follow-up for the entire 50 patient study population. Among the 49 intention-to-treat patients at the six month follow-up, one underwent coronary artery bypass and four received target lesion revascularisation for a target lesion failure rate of 8.2% and major adverse cardiac event rate of 10.2%. They add that in-segment late lumen loss was 0.31±0.52mm which met the established criteria for superiority to historical plain balloon angioplasty values ...
Background: The aim of this study was to investigate the efficacy and safety of paclitaxel-coated balloon (PCB) for the treatment of the bare-metal stent restenosis (BMS-ISR) and drug-eluting stent restenosis (DES-ISR).. Methods: This study was a prospective, multicenter, randomized (2:1) trial conducted in 208 patients with 213 in-stent restenosis lesions (BMS-ISR; 123 lesions, DES-ISR; 90 lesions) at 13 centers in Japan. Patients were randomly assigned to PCB group (PCB group, 137 patients with 142 lesions) or conventional balloon angioplasty group (BA group, 71 patients with 71 lesions). The primary endpoint was target vessel failure (TVF) at 6-month follow-up.. Results: Clinical and angiographic follow-up 6 months after intervention was performed in 207 patients (99.5%) with 208 lesions (97.7%). TVF was noted in 6.6% of PCB group and 31.0% of BA group (p,0.001). Recurrent restenosis occurred in 4.3% of PCB group and 31.9% of BA group (p,0.001). Late lumen loss was lower in PCB group than in ...
Background In-stent restenosis is considered to be a gradual and progressive condition and there is scant data on myocardial infarction (MI) as a clinical presentation. Methods and Results Of 2,462 consecutive patients who underwent percutaneous coronary intervention between June 2001 and December 2002, clinical in-stent restenosis occurred in 212 (8.6%), who were classified into 3 groups: ST elevation MI (STEMI), non-ST elevation MI (NSTEMI) and non-MI. Of the 212 patients presenting with clinical in-stent restenosis, 22 (10.4%) had MI (creatine kinase (CK) ≥2 × baseline with elevated CKMB). The remaining 190 (89.6%) patients had stable angina or evidence of ischemia by stress test without elevation of cardiac enzymes. Median interval between previous intervention and presentation for clinical in-stent restenosis was shorter for patients with MI than for non-MI patients (STEMI, 90 days; NSTEMI, 79 days; non-MI, 125 days; p=0.07). Diffuse in-stent restenosis was more frequent in MI patients ...
TY - JOUR. T1 - The basis of molecular strategies for treating coronary restenosis after angioplasty. AU - Epstein, Stephen E.. AU - Speir, Edith. AU - Unger, Ellis F.. AU - Guzman, Raul J.. AU - Finkel, Toren. PY - 1994. Y1 - 1994. N2 - Excessive smooth muscle cell proliferation significantly contributes to restenosis, which occurs in 25% to 50% of patients within 6 months of coronary angioplasty. Because successful treatment will probably depend on our acquiring a comprehensive knowledge of the molecular and cellular mechanisms involved, this report reviews 1) information relevant to the molecular and cellular mechanisms responsible for the smooth muscle cell(s) response to vascular injury, and 2) several molecular-based therapeutic strategies currently being explored as possible approaches to the control of restenosis, including recombinant DNA technology to target delivery of cytotoxic molecules to proliferating smooth muscle cell(s), antisense strategies to inhibit expression of gene ...
TY - JOUR. T1 - Drug-eluting balloon versus second generation drug eluting stents in the treatment of in-stent restenosis. T2 - a systematic review and meta-analysis. AU - Liou, Kevin. AU - Jepson, Nigel. AU - Cao, Christopher. AU - Luo, Roger. AU - Pala, Sarvpreet. AU - Ooi, Sze-Yuan. PY - 2016/12. Y1 - 2016/12. N2 - Background In-stent restenosis (ISR) remains a significant mode of stent failure following PCI. The optimal treatment strategy, however, remains undefined and the role of drug-eluting balloons (DEB) in the management of ISR is also unclear.Methods A meta-analysis was performed to compare the efficacy of DEB in the treatment of ISR against second generation drug eluting stents (DES).Results Seven studies comprised of 1,065 patients were included for analysis. The follow-up period ranged from 12-25 months. The use of DEB was associated with an inferior acute gain in minimal luminal diameter (MLD) (0.36, 95% CI: 0.16-0.57 mm), higher late loss in MLD (0.11, 0.02-0.19 mm) and a higher ...
Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ. Restenosis is a common adverse event of endovascular procedures. Procedures frequently used to treat the vascular damage from atherosclerosis and related narrowing and renarrowing (restenosis) of blood vessels include vascular surgery, cardiac surgery, and angioplasty. When a stent is used and restenosis occurs, this is called in-stent restenosis or ISR. If it occurs following balloon angioplasty, this is called post-angioplasty restenosis or PARS. The diagnostic threshold for restenosis in both ISR or PARS is ≥50% stenosis. If restenosis occurs after a procedure, follow-up imaging is not the only way to initially ...
The use of SES has been shown in randomised clinical trials to result in an in-stent lumen loss of −0.01 to 0.20 mm for de novo coronary lesions.6,7,8,9,10 Slightly higher lumen loss ranging from 0.12 (0.41) to 0.21 (0.62) mm has been reported in small registries with the use of SES for ISR lesions.21,22 In this study in-stent lumen loss in the SES group was 0.30 (0.49) mm if patients with failed IRT were included and 0.23 (0.41) mm if only patients with SES used for first time ISR were analysed. Thus, the results are comparable with those of previous studies on the use of SES for ISR.. It is important to note that not all ISR lesions have a similar risk of recurrence.13 This has to be considered if angiographic and clinical follow up results for different treatment modalities for ISR are compared. Most studies analysing the procedural and follow up results of different treatment strategies for ISR were not randomised or matched comparisons.23 In this study ISR lesions treated with SES were ...
This study demonstrated that rosiglitazone significantly reduced restenosis rate in the 6 months after coronary stenting in the type 2 diabetic patients. These effects were independent of glycemic control, since there were no significant relationships between the restenosis percentage and the changes in glucose concentrations and because the glycemic indexes were similar in the two groups, either at the baseline or at the follow-up angiography.. Because the proliferations of neointimal tissue and/or the medial vascular smooth muscle cells (VSMCs) are pivotal to the pathophysiology of a postintervention restenosis (20,21), inhibiting cellular proliferation for preventing an in-stent restenosis is a rational strategy. Although numerous therapies, including mechanical or pharmacological approaches, to block or inhibit the pathological processes of vascular proliferation have been studied, clinical trials have generally failed to recapitulate the efficacy documented in animal studies (8-11). ...
The use of drug-eluting stents and of drug-coated balloons have mitigated the prevalence of in-stent restenosis, however in-stent remains a problem that continues to affect the long-term outcomes of femoro-popliteal endovascular therapy. This paper will provide an overview on the latest data with regard to the treatment of femoro-popliteal in-stent restenosis.. ...
Treatment of in-stent restenosis.: Although in-stent restenosis is the result of neointimal hyperplasia, mechanical problems (e.g. stent underexpansion) that oc
Endovascular treatment of symptomatic peripheral arterial disease in the femoropopliteal (FP) artery is fraught with high rates of restenosis. Success of the antiproliferative drug, paclitaxel, in the coronary arteries, has lead to the investigation of paclitaxel in the peripheral arteries to treat restenosis. This article reviews restenosis rates for the major treatment modalities used in the FP segment. Use of drug-elution for restenosis is also reviewed, including the use of drug-eluting balloons and drug-eluting stents.. ...
restenosis - MedHelps restenosis Center for Information, Symptoms, Resources, Treatments and Tools for restenosis. Find restenosis information, treatments for restenosis and restenosis symptoms.
The concept of systemic pharmacological treatment to reduce inflammation after stenting has been applied in many preclinical and clinical studies with varying success.3,4,18,19 Because of a lack of drug specificity requires high dosages to achieve sustained effects on neointimal growth, systemic side-effects are of major concern and have hindered the general acceptance of systemic pharmacological approaches to prevent restenosis. Steroids have been proven to be effective in reducing neointimal growth in preclinical and clinical settings2-4,20 but, nonetheless, systemic administration of glucocorticoids to prevent in-stent restenosis could not gain acceptance in routine clinical practice because of a lack of efficacy at concentrations low enough to avoid the hazard of steroid side-effects.. The targeted use of pharmacologically modified steroids with high affinity for sites of arterial injury, as demonstrated by our study, might be a valuable approach to effectively prevent restenosis at dosages ...
Objective: Drug-eluting stents (DES) have reduced restenosis rates compared with bare-metal stents. P27 and P53 play important roles in the signal transduction leading to neointimal growth inhibition and induction of apoptosis of smooth muscle cells due to rapamycin and paclitaxel. We hypothesized that genetic variants of P27 and P53 influence the development of restenosis and the clinical outcome of patients receiving DES. Methods: Polymorphisms in the genes encoding for P27 and P53 were tested for their association with restenosis and major adverse cardiac events. P27 C-79T and P53 G72C polymorphism genotypes were determined in a series of 433 consecutive patients receiving DES. Follow-up angiography after 6 months was performed in 87% of the patients. Genotyping was performed with PCR-based methods. Results: For patients with the respective P27 C-79T and P53 G72C genotypes, the angiographic restenosis rates were between 5.0 and 22.0%, and the clinical restenosis rates were between 0.0 and ...
Results of the ISAR-DESIRE 4 Trial Presented at TCT 2015 SAN FRANCISCO - October 14, 2015 - Results from the ISAR-DESIRE 4 trial indicate that use of a scoring balloon plus a paclitaxel-coated balloon (PCB) was angiographically superior to a paclitaxel-coated balloon alone for the treatment of restenosis within limus-eluting stents.. Findings from study were presented today at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the worlds premier educational meeting specializing in interventional cardiovascular medicine.. Restenosis after drug-eluting stent implantation (DES) in patients with coronary artery disease occurs in up to 5 to 10% of cases and the most appropriate treatment strategy remains unclear. Drug-coated balloons (DCB) are novel devices that can effectively treat in-stent restenosis. Scoring balloon (SCB) devices prevent balloon slippage and enhance local plaque disruption during ...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
The argument went that the same would likely be true for reversed saphenous veins. Randomized trials in the past supported this notion. RRISC (2006) showed that angiographic restenosis occurred more frequently with BMS (33 percent vs. 14 percent with DES), but there were only 75 patients in the trial. Notably, there was no difference in major adverse cardiovascular events (MACE) at 32 months. The SOS trial (2009 with 80 patients) supported this finding with a 51 percent vs. 9 percent angiographic restenosis rate at 12 months with BMS and DES respectively. Target vessel failure also occurred more frequently with BMS at 35 months.. More recent trials, ISAR CABG and BASKET-SAVAGE (2011 and 2016 respectively) also found DES to be superior. These trials used composite endpoints of death or cardiac death, target lesion or target vessel revascularization and myocardial infarction as endpoints. That makes comparison of actual restenosis rates difficult. Nonetheless, the number of patients was larger and ...
At three-year follow-up target lesion revascularisation was significantly less in the 192Ir group (15.4% vs 48.3%; P ,0.01). The dichotomous restenosis rate at 3 years was also significantly less in 192Ir patients (33% vs 64%; P ,0.05). No events occurred at either the 6 months or 3 year follow-up to suggest an adverse effect of vascular radiotherapy. ...
The FDA approved Medtronics IN.PACT Admiral drug-coated balloon Sept. 13 to treat in-stent restenosis in patients with peripheral artery disease.
In the REMEDEE trial, the Combo stent was found to be noninferior to the PES with respect to 9-month angiographic in-stent LLL and thereby met its primary endpoint. The observed in-stent LLL of 0.39 mm for the Combo stent was greater than that reported for conventional SES, where Cypher (Cordis, Miami Lakes, Florida) LLL values have been reported up to 0.24 mm, including diabetic patients (13-15). These angiographic results are in line with the expected capture of circulating EPCs by the CD34 antibody, creating a fast and complete layer of cells leading to the covering of the stent struts. Experimental data have shown that the abluminal release of sirolimus by the Combo stent results in a similar effective dosage in the stented arterial wall, as with the omnidirectional release by the SES, yet with a drastically reduced release to the circulation (6).. Angiographic LLL has been used as a surrogate for DES efficacy in preventing angiographic restenosis and the need for repeat TLR (16,17). A ...
This study demonstrated that rosiglitazone significantly reduced restenosis rate in the 6 months after coronary stenting in the type 2 diabetic patients. These effects were independent of glycemic control, since there were no significant relationships between the restenosis percentage and the changes in glucose concentrations and because the glycemic indexes were similar in the two groups, either at the baseline or at the follow-up angiography.. Because the proliferations of neointimal tissue and/or the medial vascular smooth muscle cells (VSMCs) are pivotal to the pathophysiology of a postintervention restenosis (20,21), inhibiting cellular proliferation for preventing an in-stent restenosis is a rational strategy. Although numerous therapies, including mechanical or pharmacological approaches, to block or inhibit the pathological processes of vascular proliferation have been studied, clinical trials have generally failed to recapitulate the efficacy documented in animal studies (8-11). ...
ISR can be defined clinically or angiographically. Definitions ISR can be defined clinically or angiographically. Clinically, it is defined as the presentation of recurrent ischaemia Angiographically, ISR is the presence of >50% diameter stenosis in the stented segment. 50%-70% : moderate %-99% : severe Teirstein PS, N Engl J Med, 1997
Este video muestra cómo utilizar un modelo preclínico de bajo costo y confiable para estudiar los procesos fisiopatológicos...
In the initial evaluation, there was a significant benefit for use of the LifeStent. Results from the 12-month analyses indicate that although there was no difference in freedom from major adverse cardiac events between the control and test group, primary patency and freedom from target lesion revascularisation (TLR) were significantly increased in the patients treated with the LifeStent. In addition, results from the 24-month follow-up indicate that freedom from TLR in patients treated with the LifeStent is almost double that of patients treated with angioplasty alone. However, although the results from patients treated with the LifeStent were better overall, Scheinert added that an angioplasty-only strategy has a role in patients with less complex lesions such as those that are shorter or less-severely calcified.. ...
Vinay Malhotra, MD, a cardiologist at the Cardiac Study Center inTacoma, Wash., evaluated in-stent restenosis (ISR) and chronic totalocclusions (CTO) in the lecture series
A medical stent is sized for placement in a ureter. The stent includes a first section which includes a first material, defines a lumen, and includes a first coil completing at least one revolution. A second section of the stent includes a second material, defines a lumen, and includes a second coil completing at least one revolution. A third section defines a lumen and is located between the first and second sections. The third section includes a co-extrusion of the first and second materials. One of the first or second sections is harder than the other section.
Trouvaille Stent Équipement RFP For Sale, ou Wanted du plus grand marché médical déquipement des mondes. DOTmed.com a un des plus grands choix de nouveau, utilisés, et refourbis Stent équipement sur le marché.
Le Creuset stent j til madlavning og servering.velegnet til brug i ovn op til 260 C og under ovnens grillelement. T ler desuden mikroovn, fryser og maskinopvask. M IKKE anvendes direkte p komfuret! Le Creuset stent j har en emaljeret overflade, der er nem at reng re.
ႏွလုံးေသြးေၾကာက်ဥ္းကုသမႈတစ္ခုျဖစ္တဲ့ Stent ( စတန႔္)ထည့္တယ္ဆိုတာဘာလဲ
Denne procedure er alene gældende for MR-sektionen på Rigshospitalet. Aktuelle procedure kan naturligvis anvendes som inspirationskilde til udvikling af egne sikkerhedsforskrifter. ...
واشنطن، العاصمة ــ في ظل الاضطرابات في أوكرانيا، ومراقبة الولايات المتحدة وروسيا لتحركات كل منهما الأخرى بحذر، يبدو العالم وكأنه على شفا مواجهة طويلة أشبه بالحرب الباردة. ولكن هل هذا صحيح حقا؟. لقد قامت روسيا، التي تتهم الغرب بدعم انقلاب قام به فاشيون وإرهابيون في كييف، بضم شبه جزيرة القرم، واختبرت صاروخاً باليستياً عابراً للقارات، واحتفظت بحق التدخل عسكرياً في شرق أوكرانيا لحماية السكان الروس هناك. وفرضت الولايات المتحدة عقوبات على روسيا واعتبرت ضم شبه جزيرة القرم تصرفاً غير قانوني. ولكنها دعت أيضاً إلى التعاون لحل الموقف سلمياً وأعلنت أن ...
TY - JOUR. T1 - Brachytherapy with gamma radiation of a coronary artery for in-stent restenosis may induce the regression of in-stent restenosis of an adjacent coronary artery without angioplasty. First case report and review of the literature. AU - Movahed, Mohammad Reza. PY - 2004/10/1. Y1 - 2004/10/1. N2 - Here, we present a case of a 63-year-old male who presented with in-stent restenosis of two coronary arteries simultaneously (mid circumflex and proximal ramus). After the brachytherapy of the circumflex artery for in-stent restenosis, the patient refused the staged procedure for the ramus in-stent restenosis. After approximately 2 years, the patient underwent coronary angiography for recurrent chest pain. Surprisingly, the proximal ramus stent showed marked regression of in-stent restenosis. We hypothesized that the gamma brachytherapy of the circumflex artery could have induced the regression of in-stent restenosis of the adjacent ramus artery due to the deep tissue penetration of gamma ...
The FAIR trials objective was to assess safety and efficacy of angioplasty with drug-eluting balloon vs. standard angioplasty for the treatment of symptomatic superficial femoral artery in-stent restenosis. The primary endpoint was binary (≥50%) restenosis rate at six months as assessed by duplex ultrasound corelab adjudication (PSVR≥2.4). The secondary endpoints were primary angiographic success (,50% residual stenosis), six-month recurrent in-stent restenosis (≥70%) and 12-month recurrent in-stent restenosis (≥50%), six- and 12-month clinically-driven target lesion revascularisation, and clinical/haemodynamic assessment (walking distance, ankle brachial index, Rutherford category) at one, six and 12 months. The investigators also assessed the major adverse vascular events (MAVE) at 12 months.. Patients who had Rutherford class 2-4 lesions and superficial femoral artery in-stent restenosis between 70-100% as assessed by duplex ultrasound were included. Further, to be included, patients ...
Hello and welcome to the December issue of Vascular Disease Management. I have chosen to comment on Deepika Kalisetta and colleagues case report on Balloon Assisted Dislodgement of a Trapped Directional Atherectomy Catheter (the Ocelot device) During Treatment of In-Stent Restenosis (ISR).. Stenting of femoropopliteal arterial obstructive lesions has been demonstrated to result in higher primary patency than standard balloon angioplasty. Stenting is also routinely utilized to treat flow-limiting dissections following PTA and atherectomy. Therefore, stenting is commonly utilized in treating symptomatic femoral and popliteal arterial obstructions. Unfortunately, restenosis and reocclusion are common following stenting. Whereas stent grafts tend to develop recurrent stenosis only at the edge of the stents, standard nitinol self-expanding stents often develop diffuse in-stent restenosis secondary to neointimal hyperplasia and reocclusion when there is superimposed thrombus. Stent restenosis can ...
Boston Scientifics Jetstream atherectomy system has received CE mark for a new in-stent restenosis indication. This indication gives EU physicians another safe and effective treatment option for in-stent restenosis, a disease state that has historically been challenging to treat with traditional therapies, says a Boston Scientific press release.. The indication is supported by data from the Jetstream-ISR feasibility study, in which the device demonstrated a strong safety profile, with zero device-stent interactions. The study included long, complex lesions (62% were TASC C&D). Six-month freedom from target lesion revascularisation was 86.2% with patency at 72%.. ...
Multi-detector computed tomography angiography (MDCTA)of the coronary arteries after stenting has been evaluated in multiple studies. The purpose of this study was to perform a structured review and meta-analysis of the diagnostic performance of MDCTA for the detection of in-stent restenosis in the coronary arteries. A Pubmed and manual search of the literature on in-stent restenosis (ISR) detected on MDCTA compared with conventional coronary angiography (CA) was performed. Bivariate summary receiver operating curve (SROC) analysis, with calculation of summary estimates was done on a stent and patient basis. In addition, the influence of study characteristics on diagnostic performance and number of non-assessable segments (NAP) was investigated with logistic meta-regression. Fourteen studies were included. On a stent basis, Pooled sensitivity and specificity were 0.82(0.72-0.89) and 0.91 (0.83-0.96). Pooled negative likelihood ratio and positive likelihood ratio were 0.20 (0.13-0.32) and 9.34 (4.68-18
196 of 205 patients assigned to treatment of placebo were followed clinically and 177 had repeat angiography. There was no difference between groups in the following: average age 61 years, 22% were women, 40% were smokers, 28% diabetics, lipids, homocysteine (11μm/L), or treatment with statins (71%), beta blockers (65%), and ACIi (35%), use of stents (50%). Treatment lowered homocysteine levels from 11.1 +/- 4.3μm/L to 7.2 +/- 2.4 μm/L. The rate of restenosis was significantly lower on treatment (19.6% vs 37.6%, p = 0.01) as was the need for target vessel revascularization (10.8% vs. 22.3%, p = 0.047). The followup minimal luminal diameter and percent stenosis was also significantly better in the folate group. There was no difference in other coronary events. The benefit was predominately in those with PTCA without stenting ...
In-stent restenosis has long remained the major limitation of coronary stenting. Recent randomized trials have shown that the use of drug-eluting stents (DES) markedly reduce the risk of in-stent restenosis following treatment of de novo lesions,1-4 even lesions at high risk for in-stent restenosis.5,6 Calcified lesions are often undilatable with conventional balloons and are a predictor of late in-stent thrombosis.7 Stent underexpansion is also associated with restenosis8 and in-stent thrombosis after successful DES implantati
Clinical trial for Transluminal | Coronary Restenosis | Percutaneous Coronary | Angioplasty , Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial
OBJECTIVE: To assess the safety and efficacy of the Genous™ endothelial progenitor cell (EPC) capturing stent in conjunction with HmG-CoA-reductase inhibitors (statins) to stimulate EPC recruitment, in the treatment of patients with de novo coronary artery lesions. METHODS AND RESULTS: The HEALING IIB study was a multi-center, prospective trial, including 100 patients. The primary efficacy endpoint was late luminal loss by QCA at 6-month follow-up (FU). Although statin therapy increased relative EPC levels by 5.6-fold, the angiographic outcome at 6 month FU was not improved in patients with an overall in-stent late luminal loss of 0.76±0.50 mm. The composite major adverse cardiac events (MACE) rate was 9.4%, whereas 6.3% clinically justified target lesion revascularizations (TLRs) were observed. 2 Patients died within the first 30 days after stent implantation due to angiographically verified in-stent thrombosis. At 12 month FU, MACE and TLR increased to 15.6% and 11.5% respectively and stabilized
PARIS--(BUSINESS WIRE)--May 16, 2012-- Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing statistically significant advantages of using an IN.PACT drug-eluting balloon from Medtronic, Inc. (NYSE: MDT) over a corresponding conventional treatment for coronary and peripheral artery disease.. Medtronic IN.PACT drug-eluting balloons received CE (Conformité Européenne) mark in 2008 and 2009 and are available in many countries around the world. They are not commercially available in the United States.. BELLO The physician-initiated BELLO (Balloon Elution and Late Loss Optimization) study enrolled 182 patients across 15 hospitals in Italy to evaluate the safety and effectiveness of the Medtronic IN.PACT Falcon(TM) drug-eluting balloon versus the Taxus drug-eluting stent (DES) from Boston Scientific Corp. in reducing late lumen loss in small-vessel coronary artery disease. With both devices eluting ...
A 93 patient randomised trial of a sirolimus-coated nitinol stent vs. the same, uncoated device in relatively long lesions (mean length 8.3 ± 4.5 cm) ended with high long-term efficacy of BMS: the two-year angiographic restenosis rate was 21% in both groups. Two-year target lesion revascularisation was very low overall and there was no significantly different restenosis between the BMS and the DES arm: 13% vs. 6% (15). Nevertheless, it could be expected that this figure was twice that of the BMS group, and the difference would have reached significant figures with a bigger sample size.. Polimer-free paclitaxel-coated DES implantation or balloon dilatation (PTA), debatable results: In a subsequent larger trial, 479 symptomatic patients were assigned to polimer-free paclitaxel-coated DES implantation or balloon dilatation (PTA) of femoro-popliteal stenoses with a mean length of 6.3 ± 4 cm. (16). Patients in the balloon arm were further randomised to BMS or DES during the intervention if balloon ...
Hellenic J Cardiol 2011; 52: Original Research Long-Term Results After Drug-Eluting Stent Implantation in Diabetic Patients According to Diabetic Treatment Vassilis Voudris, Panagiotis Karyofillis,
The principal findings from the present report, representing the final 5-year analysis from the TAXUS clinical trial development program, are that in patients undergoing PCI of a single de novo lesion of varying complexity, treatment with the slow-release PES versus an otherwise identical BMS resulted in: 1) significant 1-year reductions in ischemia-driven TLR and TVR in simple and complex patients and lesions, differences that were maintained throughout 5 years of follow-up, with no evidence of late catch-up apparent; 2) nonsignificant differences in the cumulative rates of all-cause mortality, cardiac mortality, MI, and cardiac death or MI at the end of the 5-year follow-up period; 3) an increase in the 5-year cumulative rate of stent thrombosis, which reached statistical significance when defined by the pre-specified protocol definition of stent thrombosis, but not by the ARC definite or probable definition; and 4) similar rates of cardiac death or MI and protocol-defined stent thrombosis ...
12-month data from the RESTORE pilot clinical trial between December 2011 and July 2012 were also presented at TCT. The RESTORE trial was designed to evaluate safety and performance of the first generation ReZolve sirolimus-eluting bioresorbable coronary scaffold. Imaging results of patients treated with ReZolve who remained event free after treatment demonstrated a mean in-stent late loss of 0.29 mm. When imaging results for patients who had undergone retreatment for focal in-stent restenosis the mean in-stent late loss was 0.69 mm ...
A pooled analysis of safety data from Medtronics Endeavor clinical programme has affirmed the superior safety of the Endeavor drug-eluting coronary stent compared to the best-in-class Medtronic bare metal stent, Driver.
A stent is a small, expandable tube that can be inserted into a blood vessel and expanded using a small balloon during a procedure called angioplasty. A stent is used to open a narrowed or clotted blood vessel.. When the balloon inside the stent is inflated, the stent expands and presses against the walls of the artery. This traps any fat and calcium buildup against the walls of the artery and allows blood to flow through the artery. The stent helps prevent the artery from closing again (restenosis). It can also help prevent small pieces of plaque from breaking off and causing a heart attack or stroke.. To insert the stent, a flexible, thin tube (catheter) is passed through an artery in the groin or arm into the narrowed artery. Then the balloon inside the stent is inflated.. Some stents, called drug-eluting stents, are coated with a medicine to more effectively prevent restenosis. ...
Gene-eluting stents can have profound impact in the treatment of coronary restenosis, especially when the encoded protein can re-endothelialize the arterial lumen. In this study, we have examined gene...
Interventional cardiology has made lifestyle changes obsolete. Angioplasty surgery can open clogged vessels and put a stent in. But what about life after stent?
CardioMind, Inc., a developer of stents for small, difficult-to-treat blood vessels, announced today that it has begun a First-in-Human clinical trial of its drug-eluting stent.
Terumo has received the CE mark for its Ultimaster Tansei drug-eluting stent. Building on the Ultimaster stent, a press release reports, the Ultimaster Tansei features optimised technology that will benefit clinicians and their patients worldwide.
A stent is a wire mesh tube (scaffold) thats inserted into a narrowed coronary artery to keep it open and allow heart muscle to get the blood flow and oxygen it needs. Drug-eluting stents have a coating that releases a drug over time to help keep blockages from happening.. ...
Although the increased use of balloon expandable stents is a valuable contribution for diminishing the restenosis rate after PTCA 3, a number of papers reporting several severe complications have been published. The complications can be related to the site of percutaneous insertion (15% of all cases, 50% of which need surgical treatment 3,4 ) or the site of the coronary stent deployment, such as subacute stent thrombosis ( 3-5% in elective and 10-20% in emergency cases 4). In our case two complications were described: a peripheral one, a pseudoaneurysm, and a coronary one, an unsuccessful deployment of a balloon extended stent. The use of stents for lesions located in the proximal third of the LAD is a routine procedure. We also decided to use a stent in order to reduce the risk of restenosis. This type of stent is advanced across the lesion without a protective sheath. After placing the stent in the correct position, the balloon was expanded and unsuccessfully deployed, due to the fact that it ...
Thank you for your interest in spreading the word on Circulation Research.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. ...
SAN DIEGO and BUELACH, Switzerland, Sept. 24, 2018 /PRNewswire/ -- Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiroa and Xienceb drug-eluting stents (DES). The data shows statistically improved outcomes for patients treated with Orsiro across a range of clinical...
Technavio analysts forecast the global drug-eluting balloons market to grow to USD 664.35 million by 2021, at a CAGR of more than 27%.
Randomized Clinical Trial Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug-Eluting Stent In-Stent Restenosis 4
A method for inhibiting restenosis is described. The method comprises implanting a stent in a patients vasculature and simultaneously delivering a restenosis-inhibiting medicine to the treatment site by adjuvant therapy.
An intravascular stent reduces the risk of restenosis due to stent implantation by using 17beta-estradiol as a vessel healing substance after implantation of an intravascular stent. The 17beta-estradiol coats at least a portion of the surface of the stent and is adhered to the stent with an adhesive layer containing DLC (
A mounting and transfer device and method for installing a stent on a delivery device that inserts the stent into a body lumen. The device includes a generally cylindrical mandrel for receiving and frictionally holding a stent, a handle at a first end of the mandrel and a guide rod extending axially from the second of the mandrel. The second end of the mandrel has a conical recess surrounding the guide rod exit. In use, a stent is placed on the mandrel, the distal end of the guide rod is fully inserted into a guide wire lumen at an end a delivery system such as a catheter and the stent is slid from the mandrel onto the balloon and crimped in place. A tube of heat shrinkable material may be placed over the stent on the mandrel and heat shrunk to lightly press against the stent. The tube and stent are transferred to the balloon and crimped. The tube protects the stent against damage during transfer and crimping and is easily removed thereafter since crimping reduces the outside diameter of the stent to
Dr. J mark Rheudasil answered: Not removed: Very unusual to remove stents unless infected (rare). They may be redilated or a surgical bypass may be needed.
FINAL CLINICAL STUDY DATA PRESENTED TODAY BY DR. MICHAEL DAKE AT THE TRANSCATHETER CARDIOVASCUALR THERAPEUTICS (TCT) CONFERENCE IN WASHINGTON, DC VANCOUVER, Sep
Angioplasty has completely transformed the treatment of coronary artery disease and is widely used, with more than 800,000 procedures performed worldwide per year. However, the enthusiasm for angiopla
A composite intraluminal device is deployable within a body vessel. The composite device includes an elongate radially expandable tubular stent having an interior luminal surface and an opposed exterior surface extending along a longitudinal stent axis. A stent cover is formed of unsintered ePTFE which is expandable. The stent cover is positioned about the stent so as to permit expansion of the cover upon the radial expansion of the stent.
The present invention is directed to a stent for use in a bifurcated body lumen having a main branch and a side branch. The stent comprises a radially expandable generally tubular stent body having proximal and distal opposing ends with a body wall having a surface extending therebetween. The surface has a geometrical configuration defining a first pattern, and the first pattern has first pattern struts and connectors arranged in a predetermined configuration. The stent also comprises a branch portion comprised of a second pattern, wherein the branch portion is at least partially detachable from the stent body.
The present invention is directed to a stent for use in a bifurcated body lumen having a main branch and a side branch. The stent comprises a radially expandable generally tubular stent body having proximal and distal opposing ends with a body wall having a surface extending therebetween. The surface has a geometrical configuration defining a first pattern, and the first pattern has first pattern struts and connectors arranged in a predetermined configuration. The stent also comprises a branch portion comprised of a second pattern, wherein the branch portion is at least partially detachable from the stent body.
A stent includes a first stent section, a second stent section, and at least one connecting member. The connecting member has a first end attached to the first stent section, a second end attached to the second stent section and a physically separable portion.
What Medical Conditions Are Treated with a Stent? - Learn how stents are used to treat blockages and how a stent may reduce the risk of a heart attack. Watch this...
A patient that has had a kidney stent inserted will be able to eat normally and to have sex normally (if there is a thread attached to the stent then there cannot be any sex), but the patient will...
Royal Copenhagen stent jsfigur #21675 *oprejst siddende bj rn* Royal Copenhagen stent jsfigur #21675 af Knud Kyhn i Sung glasur, 1. sortering, H. 18 ...
发现 192-120 Stent 设备 For Sale或者 Wanted 从世界最大的医疗设备市场。 DOTmed.com有其中一种最大的选择新,半新和再磨光 192-120 Stent 设备在市场上。
Stent Veterella je ur en k terapii trache ln ho kolapsu u ps . Zav d c syst m s komprimovan m stentem je ur en pro implantaci do stenotick pr du nice pod skiaskopickou nebo endoskopickou kontrolou.. ...
"Prevention of Coronary Restenosis". Cardiology in Review. 7 (4): 219-231. doi:10.1097/00045415-199907000-00014. PMID 10423674. ...
February 1988). "Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative ... 15 March 2008). "A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery ... 2008). "A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions ( ... 14 March 2009). "A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple ...
... is used in drug-eluting coronary stents as an immunosuppressant to prevent restenosis. Abbott Vascular produce an ...
"Anti-HLA antibodies are associated with restenosis after percutaneous coronary intervention for cardiac allograft vasculopathy ... Woollett, IF; Pinney, S; Magnano, AR (2005). "Balloon dilatation of coronary sinus spasm during placement of a biventricular ... Pinney, SP; Wasserman, HS (2002). "Anterior myocardial infarction, acute aortic dissection and anomalous coronary artery". J. ...
... reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. ...
"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis ... Ticlopidine is FDA approved for the prevention of strokes and, when combined with aspirin, for patients with a new coronary ... Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare ... 1996). "A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents". N ...
"Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis". ... In the coronary circulation, angiography of coronary artery responses to vasoactive agents may be used to test for endothelial ... It has shown an 80% sensitivity and 86% specificity to diagnose coronary artery disease when compared against the gold standard ... This results suggests that this peripheral test reflects the physiology of the coronary endothelium. Since NO maintains low ...
Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. ...
... is used as an antiproliferative agent for the prevention of restenosis (recurrent narrowing) of coronary and ... May 2001). "Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis". ... Paclitaxel drug-eluting stents for coronary artery placement are sold under the trade name Taxus by Boston Scientific in the ...
... and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary ... Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo- ... in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo- ... Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA) Reviparin is a low molecular ...
2001). "Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis". ... His clinical interests include high risk and complex coronary intervention, treatment of hypertrophic cardiomyopathy, including ... could prevent restenosis. His research interests include delivery of stem cells to the heart for repair of myocardial ...
... coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model". ...
Clinically significant CAV may require percutaneous coronary interventions for focal disease, but the likelihood of restenosis ... Similar to coronary artery disease in those who have not had a heart transplant, risk factors to CAV include high blood ... This can be seen to affect the whole length of the coronary arteries and often the smaller arteries. Calcification does not ... The severity of CAV is defined by the degree of narrowing of the coronary arteries and the presence of restrictive heart ...
... , or ABT-578, was originally used on Abbott's coronary stent platforms to reduce early inflammation and restenosis; ... Restenosis is typically described by clinical trials in a binary approach, otherwise known as "binary restenosis" or just " ... development of thrombosis which impedes the efficiency of coronary stents, haemorrhagic and restenosis complications are ... The first human coronary stent implantation was first performed in 1986 by Puel et al. However, there are complications ...
... can be used in the treatment of coronary in-stent restenosis, in which a catheter is placed inside blood vessels ... for the treatment of coronary in-stent restenosis. The dose rate of brachytherapy refers to the level or 'intensity' with which ... "Guidelines for Percutaneous Coronary Interventions: the Task Force for Percutaneous Coronary Interventions of the European ... In treating In-stent restenosis (ISR) Drug Eluting stents (DES) have been found to be superior to Intracoronary Brachytherapy ( ...
Controlled amounts of 90Sr and 89Sr can be used in treatment of bone cancer, and to treat coronary restenosis via vascular ...
... he is known to have established a radiation therapy department at the hospital for the treatment of coronary restenosis. Later ... Gambhir, known to have specialized in non-surgical coronary interventional techniques, is reported to have performed over ... he is reported to have performed over 10,000 coronary interventions. The Government of India awarded him the fourth highest ...
The antiproliferative effect of sirolimus has also been used in conjunction with coronary stents to prevent restenosis in ... A sirolimus-eluting coronary stent was marketed by Cordis, a division of Johnson & Johnson, under the tradename Cypher. However ... "Cypher Sirolimus-eluting Coronary Stent". Cypher Stent. Archived from the original on 27 April 2003. Retrieved 1 April 2008. ... Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant ...
... which is used for treatment of re-stenosis of coronary arteries. This is a breakthrough for Kosovo medicine and the first time ... Many of the newest treatments for coronary heart disease are performed within "Heart Hospital "EDA" through minimally invasive ... coronary artery stenting, ECG monitoring, and ECHO monitoring. Their doctors are currently participating at the worldwide ...
... provide a less durable treatment for atherosclerosis and be more prone to restenosis relative to vascular bypass or coronary ... Coronary Angioplasty is indicated for coronary artery disease such as unstable angina, NSTEMI, STEMI and spontaneous coronary ... coronary arteries of the heart found in coronary heart disease. These stenotic segments of the coronary arteries arise due to ... A percutaneous coronary intervention (PCI), or coronary angioplasty with stenting, is a non-surgical procedure used to improve ...
... a landmark paper on the use intravascular stents in humans to prevent occlusion and re-stenosis after angioplasty of coronary ... Berlin: SpringerVerlag; 1984; 29-36 The SoS Investigators: Coronary artery bypass surgery versus percutaneous coronary ... Coronary Stents, Springer 1992 (ISBN 9780387545417) (Coronary Stents) U. Sigwart: Endoluminal Stenting, W. B. Saunders 1996 ( ... Lancet 1995;346:211-214 Sigwart U, Grbic M, Payot M, Goy J-J, Essinger A, et al.: Ischemic events during coronary artery ...
It was used as a scaffold to prevent the vessel from closing and to avoid restenosis in coronary surgery-a condition where scar ... The first use of a coronary stent is typically attributed to Jacques Puel [fr] and Ulrich Sigwart when they implanted a stent ... Garg S, Serruys PW (2010). "Coronary Stents: current status". J Am Coll Cardiol. 56. doi:10.1016/j.jcc.2010.06.007. Puranek AS ... Coronary Stent Drug-Eluting Stents - Angioplasty.Org Cardiovascular and Interventional Radiological Society of Europe The ...
... treatment of coronary artery bypass grafts, treatment of polycystic kidney disease, redirection of drug metabolism, treatment ... Morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty, ...
... by SmithKline Beecham in partnership with Kissei for prevention of restenosis after percutaneous transluminal coronary ... September 2002). "Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial". Circulation. 106 (10): ...
For instance, a coronary stent patient who develops restenosis may experience recurrent chest pain (angina) or suffer from a ... This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ. Restenosis is a common ... Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually ... When a stent is used and restenosis occurs, this is called in-stent restenosis or ISR. If it occurs following balloon ...
... restenosis, thrombosis or aneurysmal enlargement of the coronary artery lumens; heart chamber size; heart muscle contraction ... A coronary catheterization is a minimally invasive procedure to access the coronary circulation and blood filled chambers of ... that coronary catheterization does not allow the recognition of the presence or absence of coronary atherosclerosis itself, ... Coronary artery luminal narrowing reduces the flow reserve for oxygenated blood to the heart, typically producing intermittent ...
"Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox ... Smoking can cause atherosclerosis, leading to coronary artery disease and peripheral arterial disease. ... decrease coronary flow velocity reserves, and reduce heart rate variability, potentially increasing the risk of heart attack.[ ... "Smoke-free legislation and hospitalizations for acute coronary syndrome". The New England Journal of Medicine. 359 (5): 482-91 ...
... at risk-a treatment with paclitaxel-eluting balloon followed by BMS may reduce the incidence of coronary restenosis or ... "Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery ... Percutaneous coronary intervention (PCI) is a procedure used to treat narrowing of the coronary arteries of the heart found in ... Coronary angioplasty, also known as percutaneous transluminal coronary angioplasty (PTCA), because it is done through the skin ...
"Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention". Circulation 104 (7): 773. ...
This process is undergoing pre-clinical trials in humans and may be used to treat patients suffering coronary heart disease, ... This showed that current strategies to prevent restenosis after angioplasty of blocked arteries may have been targeted in the ... This 'Grow Your Own Arteries' technique is helping patients survive coronary heart disease, renal failure and other life- ... have potential use as access fistulae for haemodialysis patients and as coronary artery bypass grafts. She has used the same ...
... coronary artery disease, heart arrhythmia and peripheral artery disease. Radiation-induced fibrosis, vascular cell damage and ... vascular restenosis, and heterotopic ossification. The use of radiation therapy in non-malignant conditions is limited partly ...
Dong Z, Zheng J (September 2017). "Anticoagulation after coronary stenting: a systemic review". British Medical Bulletin. 123 ( ... Restenosis from stents[27]. *Cardiopulmonary bypass (or any other surgeries requiring temporary aortic occlusion)[28] ... following acute coronary syndrome". European Heart Journal. 32 (20): 2541-54. doi:10.1093/eurheartj/ehr334. PMC 3295208. PMID ... The development of letaxaban was discontinued for acute coronary syndrome in May 2011 following negative results from a Phase ...
"Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention". Circulation. 104 (7): 773 ...
Wöhrle, Jochen (2012-10-01). "Drug-Coated Balloons for Coronary and Peripheral Interventional Procedures" (in en). Current ... 2012-12-01). "Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty". Circulation: Cardiovascular ...
Restenosis from stents. In these cases, anticoagulation therapy can prevent formation of dangerous clots or prevent growth of ... following acute coronary syndrome". European Heart Journal. 32 (20): 2541-54. doi:10.1093/eurheartj/ehr334. PMC 3295208. PMID ... The development of letaxaban was discontinued for acute coronary syndrome in May 2011 following negative results from a Phase ...
"Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis". ... In the coronary circulation, angiography of coronary artery responses to vasoactive agents may be used to test for endothelial ... specificity to diagnose coronary artery disease when compared against the gold standard, acetylcholine angiogram.[10] This ... Sirolimus eluting stents were previously used because they showed low rates of in-stent restenosis, but further investigation ...
... provide a less durable treatment for atherosclerosis and be more prone to restenosis relative to vascular bypass or coronary ... A coronary angiogram (an X-ray with radio-opaque contrast in the coronary arteries) that shows the left coronary circulation. ... A coronary angioplasty is a therapeutic procedure to treat the stenotic (narrowed) coronary arteries of the heart found in ... A percutaneous coronary intervention is first performed. A PCI used with stable coronary artery disease reduces chest pain but ...
"Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox ...
"Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention". Circulation 104 (7): 773. ...
... rapamycin has also shown to be effective for preventing coronary artery re-stenosis and for the treatment of neurodegenerative ... Food and Drug Administration approved sirolimus-eluting coronary stents, which are used in patients with narrowing of coronary ... "CYPHER Sirolimus-eluting Coronary Stent - P020026". Food and Drug Administration. Retrieved 25 September 2012.. ...
His research has included work in determining how coronary hemodynamics drive the progression of coronary atherosclerosis1 and ... such as restenosis or formation of a new blockage. Outstanding Postdoc Award (1 of 4 awarded in School of Medicine), Emory ... "Coronary Artery Wall Shear Stress Is Associated With Progression and Transformation of Atherosclerotic Plaque and Arterial ... Remodeling in Patients With Coronary Artery Disease," Circulation, vol. 124, no. 7, pp. 779-788, 2011. J. Bedoya, C. A. Meyer, ...
"The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes". New England Journal of Medicine. 326 (4): 242-50 ... Poon, Michael; Badimon, Juan Jose; Fuster, Valentin (2002). "Viewpoint Overcoming restenosis with sirolimus: From alphabet soup ... "The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes". New England Journal of Medicine. 326 (5): 310-8 ... Fuster, V; Fallon, JT; Nemerson, Y (November 1996). "Coronary thrombosis". Lancet. 348 Suppl 1: s7-10. doi:10.1016/s0140-6736( ...
... a process called restenosis. The stent is usually placed within the peripheral or coronary artery by an interventional ... coronary-artery bypass grafting in multivessel coronary disease". N. Engl. J. Med. 358 (4): 331-41. doi:10.1056/NEJMoa071804. ... A drug-eluting stent (DES) is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary ... The first procedure to treat blocked coronary arteries was coronary artery bypass graft surgery (CABG), wherein a section of ...
Restenosis is the recurrence of stenosis after a procedure. The resulting syndrome depends on the structure affected. Examples ... of vascular stenotic lesions include: Intermittent claudication (peripheral artery stenosis) Angina (coronary artery stenosis) ... Atresia Restenosis Notes OED 2nd edition, 1989, as /stɪˈnəʊsɪs/. Entry "stenosis" in Merriam-Webster Online Dictionary. " ...
Cypher is a brand of drug-eluting coronary stent from Cordis Corporation, a Cardinal Health company. During a balloon ... of normal cells while the artery heals which reduces the chance of re-blockage in the treated area known as restenosis, and ... CS1 maint: discouraged parameter (link) "CYPHER™ Sirolimus-eluting Coronary Stent - P020026". FDA.gov. U.S. Food and Drug ...
Gruentzig performed coronary angioplasties in 169 patients in Zurich, while teaching the practice of coronary angioplasty to a ... The first study of these individuals revealed an incredible lack of restenosis (zero percent restenosis) at six months. This ... RITA Investigators (1993). "Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment ... Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day ...
These mediators can precipitate coronary artery spasm and accelerate the rupture of atheromatous plaques of the coronary ... Type III is subdivided now to stent thrombosis (subtype a) and stent restenosis (subtype b). The management of these patients ... SPECT have revealed severe myocardial ischemia while coronary angiography showed normal coronary arteries. Furthermore, with ... Acute coronary event protocol is applied and type II can be treated similarly to type I for cardiac symptom control. Glucagon ...
Left main or multi vessel coronary artery disease. Need for open heart surgery within 30 days. Left ventricular ejection ... Long term complications include restenosis of the endarterectomy bed, although the clinical significance of this is ...
On 17 January 1990 Sahota performed the first coronary angioplasty in North India and nine more followed in the week that the ... he holds a total of 24 patents and many other medical inventions such as Red Laser Light for prevention of Restenosis, Fibrin ... He performed the first coronary Angioplasty in many hospitals around the world including India, Mexico, Russia, Ukraine and the ... 4. Harvy Sahota, et al., (2000), "Long-term Follow-up after Coronary Stenting and Intravascular Red Laser Therapy," American ...
Disease relevance of Coronary Restenosis. *Potential role of human cytomegalovirus and p53 interaction in coronary restenosis [ ... High impact information on Coronary Restenosis. *Decreased rate of coronary restenosis after lowering of plasma homocysteine ... Chemical compound and disease context of Coronary Restenosis. *In contrast, late coronary restenosis developed in only 7 (11%) ... Costs of coronary restenosis (Lovastatin Restenosis Trial). Gilbert, S.P., Weintraub, W.S., Talley, J.D., Boccuzzi, S.J. Am. J ...
Restenosis after successful coronary angioplasty: pathophysiology and prevention. N Engl J Med. 1988;318:1734-1737. ... Restenosis after coronary angioplasty: potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79: ... Impact of Cilostazol on Restenosis After Percutaneous Coronary Balloon Angioplasty. Etsuo Tsuchikane, Atsunori Fukuhara, Tohru ... Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon: a quantitative angiographic study in ...
Beyond Restenosis. Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials. Donald E. Cutlip, Amit G. Chhabra ... Beyond Restenosis. Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials ... Beyond Restenosis. Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials ... Beyond Restenosis. Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials ...
Study of many percutaneous coronary intervention procedures imply that employing drug-eluting stents differ among U.S. ... Drug-Eluting Stents Do Not Affect Risk of Restenosis of Coronary Artery in Angioplasty Patients. The risk of restenosis ( ... Also it is only modestly correlated with the patients risk of coronary artery restenosis (renarrowing), states a report ... Employing Drug-Eluting Stents Differ Broadly, Moderately Correlated With Coronary Artery Restenosis Risk. ...
2238 T/C polymorphism and restenosis in coronary arteries stented due to the coronary artery disease (CAD).. ER - ... 2238 T/C polymorphism and restenosis in coronary arteries stented due to the coronary artery disease (CAD).. ... ATRIAL NATRIURETIC PEPTIDE: IS ANP ASSOCIATED WITH RESTENOSIS AFTER CORONARY ARTERY STENTING?. ... Publikace , ATRIAL NATRIURETIC PEPTIDE: IS ANP ASSOCIATED WITH RESTENOSIS AFTER CORONARY ARTERY STENTING?. ...
Objective To evaluate the performance of Dual source CT coronary angiography (DSCT-CA) in the detection of in-stent restenosis ... Setting Many patients undergo coronary artery stenting; availability of a non-invasive modality to detect in-stent restenosis ... Conclusion DSCT-CA performs well in the detection of in-stent restenosis. Although DSCT-CA leads to frequent false positive ... Design / Patients We prospectively evaluated 100 patients (78 males, age 62 ± 10) with chest pain after coronary stenting. DSCT ...
Repeat coronary angioplasty has become the standard approach to a first restenosis. However, the long-term outcome of such a ... Repeat coronary angioplasty as treatment for restenosis J Am Coll Cardiol. 1992 May;19(6):1310-4. doi: 10.1016/0735-1097(92) ... Repeat coronary angioplasty has become the standard approach to a first restenosis. However, the long-term outcome of such a ... The combined angiographic and clinical restenosis rate was 48%. Repeat angioplasty as treatment for restenosis is an effective ...
To find out the predictive value of the ΣΔST/ΔHR index for restenosis after percutaneous coronary intervention (PCI). Subjects ... At 6-9 months, angiographic restenosis was measured as an in-segment late loss of the stented coronary artery in addition to ... Schroeder E,Marchandise B,de Coster P,Brichant C,Mitri K,Pieters D,Kremer R. Detection of restenosis after coronary angioplasty ... OBJECTIVE: To find out the predictive value of the ΣΔST/ΔHR index for restenosis after percutaneous coronary intervention (PCI ...
... clinicaltrials.gov Different healing responses after treatment of bare metal stent restenosis with implantation of an ... Home » Topics » Stent » Research » SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study ... More From BioPortfolio on "SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study". * ... SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study. 2014-08-27 03:16:02 , BioPortfolio ...
Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 ... Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 ... Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 ... Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 ...
OBJECTIVE-Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging ... Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS: Restenosis after arterial injury caused by coronary stenting in patients with ... This study demonstrated that rosiglitazone significantly reduced restenosis rate in the 6 months after coronary stenting in the ... Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes. ...
Coronary Atherosclerosis , PIoglitazone for PrEvention of Restenosis in Diabetic Patients ... restenosis after successful implantation of a sirolimus-eluting coronary stent for treatment of de-novo "complex" coronary ... Restenosis requiring reintervention is still a limitation of percutaneous coronary angioplasty. Despite the use of Drug eluting ... Quantitative Coronary Angiography Baseline, postprocedural, and follow-up coronary angiograms will be digitally recorded and ...
Coronary Artery Restenosis Terminated Phase 2 Trials for Serine (DB00133). Back to Coronary Artery Restenosis ... Serp-1 for the Treatment of Acute Coronary Syndrome. Diagnostic. *Serine (DB00133) ...
Proximal coronary artery intervention: Stent thrombosis, restenosis and death. Calais, Fredrik Lagerqvist, Bo Uppsala ... Conclusions: Following proximal coronary artery intervention restenosis was more frequent in the LAD than in the LCX. Solely in ... No differences in restenosis or ST were seen between the LAD and the RCA. The frequency of restenosis and ST was higher in the ... Background: Percutaneous coronary intervention (PCI) of lesions in the proximal left anterior descending coronary artery (LAD) ...
... Am J Cardiol. ... 3 polymorphism of GPIIb are more susceptible to developing thrombosis and restenosis after coronary stent placement. We ... of platelet GPIIb is not associated with an increase in the risk of thrombosis and restenosis over 1 year after coronary stent ... The incidence of stent restenosis was 37.3% in HPA-3a/a, 36.2% in HPA-3a/b, and 34.6% in HPA-3b/b patients (p = 0.724). Event- ...
Asymmetric dimethylarginine may influence the process of restenosis after coronary angioplasty. The aim of the study was to ... Endothelial dysfunction and restenosis following percutaneous coronary intervention. Int J Cardiol 2007; 119: 362-7. 25. Suda O ... The aim of the study was to determine if initial plasma ADMA level could predict restenosis after coronary angioplasty and ... The role of biochemical factors in the pathogenesis of coronary artery restenosis after PCI continues to be the subject of ...
Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents. ... Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents. ... reports a relative high restenosis rate in a longer follow-up duration. Restenosis seems to become an important issue regarding ... and primary stenting have been shown to be safe and effective with lower restenosis rate. Coronary equipments are ideal for ...
Percutaneous Coronary , Angioplasty , Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of ... Restenosis is the major adverse effect of coronary stent implantation. Drug-eluting stent has markedly reduced restenosis as ... Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial ... the main cause of repeat coronary intervention after drug-eluting stent implantation. After coronary stent implantation, ...
PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions. The ... PROVIDENCE: Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With de Novo Coronary Lesions. ... Coronary Artery Disease Diabetes Mellitus Procedure: Percutaneous Coronary Intervention (PCI) Phase 2 Phase 3 ... Target lesion is due to restenosis. *3 vessel coronary artery disease defined as ≥70% ischemia producing lesions in 3 different ...
Objective Systematic investigation of restenosis after percutaneous coronary intervention (PCI) with bare metal stents (BMS) or ... Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography ... Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography ... Binary restenosis was detected in 2643 (26.4%) patients. Use of first generation DES versus BMS (OR 0.35, 95% CI 0.31 to 0.39) ...
2014) in Coronary artery restenosis, Stent sizing without intravascular imaging: impact on restenosis, ed Lofti A. (Nova ... Aggressive Post-Dilation of Coronary Stents and Restenosis Message Subject (Your Name) has forwarded a page to you from JACC: ... 1) that described the incidence of the risk factors for stent fracture and restenosis. They highlight an under-recognized ... 2014) Overaggressive stent expansion without intravascular imaging: impact on restenosis. Heart Asia 6:32-35. ...
Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting ... in coronary arteries. Download Prime PubMed App to iPhone, iPad, or Android ... AgedCoronary Artery DiseaseCoronary RestenosisFemaleFolic AcidFollow-Up StudiesGenetic Predisposition to DiseaseGenotype ... The need for restenosis-driven reintervention (clinical restenosis) was 18.8% in subjects with low homocysteine concentrations ...
... in the treatment of coronary artery disease and relatively high restenosis rate following PCI require the introduction of ... The increasing role of percutaneous coronary interventions (PCI) ... for the assessment of risk of coronary restenosis. METHODS: ... Coronary Angiography. Coronary Restenosis / radiography, ultrasonography*. Coronary Stenosis / therapy*. Echocardiography, ... In a group of 11 patients with restenosis confirmed in the coronary angiography, one-year follow-up DSE was found positive in 9 ...
Decreased Rate of Coronary Restenosis After Lowering of Plasma Homocysteine Levels - Decreased Rate of Coronary Restenosis ... Keywords: Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Coronary Restenosis, Lipids, Constriction, Pathologic, ... YOU ARE HERE: Home , Latest in Cardiology , Decreased Rate of Coronary Restenosis After Lowering of Plasma Homocysteine Levels ... Patients with acute coronary syndromes or creatinine >1.8mg/dl were excluded. The specifics of the PTCA, adjunctive treatment ...
Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery ... AgedAngioplasty, Balloon, CoronaryCoronary Artery BypassCoronary RestenosisFemaleHealth Status IndicatorsHumansMaleMultivariate ... Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery ... "Risk of Restenosis and Health Status Outcomes for Patients Undergoing Percutaneous Coronary Intervention Versus Coronary Artery ...
... have a higher incidence of restenosis after coronary stenting, and, if so, whether restenosis is attributable to lesion or ... Restenosis after Arterial Injury Caused by Coronary Stenting in Patients with Diabetes Mellitus Joseph P. Carrozza, MD; Richard ... Restenosis after Arterial Injury Caused by Coronary Stenting in Patients with Diabetes Mellitus. Ann Intern Med. 1993;118:344- ... Review: CABG or stents compared with medical therapy in stable coronary artery disease Annals of Internal Medicine; 161 (8): ...
High Plasma Levels of Osteopontin in Patients With Restenosis After Percutaneous Coronary Intervention. Ryuichi Kato, Yukihiko ... Potential roles of osteopontin and αvβ3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl ... Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med. 2003; 3: S4-S9. ... CAD was defined as at least one coronary artery having ,50% luminar diameter stenosis. Restenosis was defined as ,50% luminar ...
All patients underwent elective coronary stent implantation in a stenosis of a major coronary vessel. Balloon inflations were ... we therefore tested the relationship between the ACE gene polymorphism and the restenosis rate after coronary stent ... Angiotensin-converting enzyme insertion/deletion polymorphism does not influence the restenosis rate after coronary stent ... In all, 39 patients (25.3%) had significant restenosis: 12 DD patients (25.0%), 18 ID patients (21.7%) and 9 II patients (39.1 ...
... receptor in relation to severity of coronary artery disease and in-stent restenosis after coronary stenting. ... A subsequent coronary angiography was performed 6-9 months later for suspected restenosis for patients (N=273) who underwent ... Conclusion: Genetic polymorphisms of RAS are not associated with in-stent restenosis after coronary stenting. However, the ... Percutaneous coronary intervention (PCI) is an effective technique for coronary revascularization but a considerable number of ...
... Svedman, Cecilia LU ; ... The restenosis rate was evaluated. RESULTS: We found a correlation between contact allergy to gold, gold stent, and restenosis ... The restenosis rate was evaluated. RESULTS: We found a correlation between contact allergy to gold, gold stent, and restenosis ... The restenosis rate was evaluated. RESULTS: We found a correlation between contact allergy to gold, gold stent, and restenosis ...
  • Background -Restenosis after percutaneous transluminal coronary (balloon) angioplasty (PTCA) remains a major drawback of the procedure. (ahajournals.org)
  • Although there is an increasing number of indications for percutaneous transluminal coronary (balloon) angioplasty (PTCA) for revascularization in cases of coronary artery disease, restenosis after PTCA remains a serious problem associated with this procedure. (ahajournals.org)
  • Research founded on over 1.5 million percutaneous coronary intervention procedures like balloon angioplasty or stent placement to open narrowed coronary arteries, imply that the use of drug-eluting stents differ widely among U.S. physicians. (medindia.net)
  • Repeat coronary angioplasty has become the standard approach to a first restenosis. (nih.gov)
  • Forty-nine patients (10.6%) underwent a third angioplasty procedure at the same site, 55 (11.8%) had coronary bypass surgery and 33 (7.1%) underwent angioplasty at a different site. (nih.gov)
  • Repeat angioplasty as treatment for restenosis is an effective approach associated with a high success rate, low incidence of procedural complications, and sustained functional improvement in combination with an acceptable rate of bypass surgery. (nih.gov)
  • However, there is a trend toward diminished angioplasty efficacy after a second restenosis. (nih.gov)
  • Restenosis requiring reintervention is still a limitation of percutaneous coronary angioplasty. (centerwatch.com)
  • Methods: From May 2005, to May 2011 we identified all PCIs for proximal, one-vessel coronary artery disease in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). (diva-portal.org)
  • Unfortunately, the long-term efficacy of angioplasty is limited by the recurrent narrowing within the dilated part of the artery, which is known as restenosis. (termedia.pl)
  • Injury of the endothelium within epicardial arteries occurring during angioplasty is believed to activate the process of restenosis [1]. (termedia.pl)
  • Asymmetric dimethylarginine is regarded as a new cardiovascular risk factor and it may potentially influence the process of restenosis occurring after coronary angioplasty. (termedia.pl)
  • The aim of the study was to determine if initial plasma ADMA level could predict restenosis after coronary angioplasty and stenting. (termedia.pl)
  • Stenting offers salvage following unsuccessful balloon angioplasty, and primary stenting have been shown to be safe and effective with lower restenosis rate. (clinicaltrials.gov)
  • A double-blind, prospective, randomized trial of treatment with folic acid (1mg), vitamin B-12 (400ugm), and pyridoxine (10mg) vs. matching placebo in patients following successful angioplasty of at least one coronary stenosis of 50% or greater. (acc.org)
  • Restenosis after angioplasty is caused by negative arterial remodeling and neointimal proliferation, whereas in-stent restenosis is caused mainly by neointimal proliferation. (ahajournals.org)
  • The FACT was a prospective multicenter, double-blind, randomized trial designed to evaluate whether treatment with nadroparin, a low-molecular-weight heparin, started 3 days before coronary angioplasty and continued for 3 months, affects angiographic restenosis or clinical outcomes. (acc.org)
  • Pretreatment with the low-molecular-weight heparin nadroparin continued for 3 months after balloon angioplasty will have a beneficial effect on angiographic restenosis or on adverse clinical outcomes. (acc.org)
  • Occurrence of death, nonfatal target lesion myocardial infarction, coronary artery bypass graft surgery, or repeat target-vessel angioplasty within the 6 months after the procedure. (acc.org)
  • Elective coronary angioplasty was performed on 354 patients who were treated with daily subcutaneous nadroparin (0.6 mL of 10 250 anti-Xa IU/mL) or placebo injections started 3 days before angioplasty and continued for 3 months. (acc.org)
  • This suggests that the superiority of CS over balloon angioplasty, in terms of restenosis, might also apply to subgroups of patients that were not included in the recent randomized studies. (onlinejacc.org)
  • Balloon angioplasty (BA) has become an established treatment for patients with coronary artery disease (CAD) but remains plagued by the problem of restenosis [1, 2] . (onlinejacc.org)
  • Recent improvements in the technique of stent implantation and in antithrombotic regimens have allowed CS to be performed in a high proportion of patients undergoing repeat percutaneous transluminal coronary angioplasty (PTCA) [11, 12] . (onlinejacc.org)
  • After successful percutaneous transluminal coronary angioplasty (PTCA), restenosis occurs in a relatively high proportion of patients. (eur.nl)
  • High dose rate brachytherapy for prevention of restenosis after percutaneous transluminal coronary angioplasty: preliminary dosimetric tests of a new source presentation. (semanticscholar.org)
  • If the results in this model apply to human coronary arteries, restenosis may depend on the degree of vessel injury sustained during angioplasty. (elsevier.com)
  • Excessive smooth muscle cell proliferation significantly contributes to restenosis, which occurs in 25% to 50% of patients within 6 months of coronary angioplasty. (elsevier.com)
  • To determine the usefulness of dobutamirte stress echocardiography (DSE) as a non invasive way for detecting restenosis after percutaneous transluminal coronary angioplasty (PTCA), the results of coronary angiography and DSE were compared 6 months after PICA in 40 patients (28 males & 12 females, mean age49.7 +10.2 years). (bu.edu.eg)
  • Coronary angioplasty and endovascular procedures remain effective methods of providing symptomatic relief to a large number of patients with vascular narrowing. (uthscsa.edu)
  • Bailey, S. R. / Coronary restenosis after angioplasty . (uthscsa.edu)
  • This multicenter case control study assessed angiographic and clinical outcomes of 137 consecutive procedures in 125 patients treated for ISR with either PTCA alone (n=58) or excimer laser assisted coronary angioplasty (ELCA, n=67). (yyu.edu.tr)
  • Angioplasty , a type of percutaneous coronary intervention (PCI), is a procedure used to open up blocked arteries. (healthline.com)
  • Balloon angioplasty is the procedure used to treat coronary stenosis. (healthline.com)
  • Do Long-term Inflations Reduce the Occurrence of Acute Complications after Coronary Balloon Angioplasty? (springer.com)
  • Percutaneous Transluminal Coronary Angioplasty is presently the widest used non-surgi- cal method for the treatment of stenotic lesions in coronary artery disease. (springer.com)
  • Brachytherapy with gamma radiation of a coronary artery for in-stent restenosis may induce the regression of in-stent restenosis of an adjacent coronary artery without angioplasty. (elsevier.com)
  • Based on our observation, we believe that in the treatment of in-stent restenosis of a coronary artery, the initial balloon angioplasty may not be as important as the radiation itself. (elsevier.com)
  • This observation warrants further study to evaluate the effect of external or internal radiation on in-stent restenosis without balloon angioplasty. (elsevier.com)
  • Four months later after cutting balloon angioplasty, the patient received an intracoronary stent when he once again presented with recurrent ACS in the setting of restenosis. (biomedcentral.com)
  • Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. (duke.edu)
  • Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). (duke.edu)
  • OBJECTIVES: This study sought to compare the frequency of restenosis, reocclusion and adverse cardiovascular events after angioplasty of occluded versus nonoccluded coronary arteries. (duke.edu)
  • BACKGROUND: Angioplasty of chronically occluded coronary arteries is believed to be associated with a higher frequency of restenosis and reocclusion than angioplasty of subtotal stenoses. (duke.edu)
  • METHODS: The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Restenosis (MARCATOR) was a placebo-controlled trial with angiographic follow-up to determine the effect of the angiotensin-converting enzyme inhibitor cilazapril on the frequency of restenosis. (duke.edu)
  • We identified 139 patients with successful angioplasty of a coronary occlusion (Group 1) and compared the frequency of restenosis, reocclusion and adverse cardiovascular events with that in 1,295 patients with successful angioplasty of a subtotal stenosis (Group 2). (duke.edu)
  • CONCLUSIONS: The frequency of restenosis was slightly but not significantly greater after successful angioplasty of an occluded artery than after angioplasty of a subtotal stenosis. (duke.edu)
  • The following is a study of the response of de novo versus restenosis coronary lesions to pulsed-wave, mid-infrared (holmium:YAG) laser assisted angioplasty. (elsevier.com)
  • Repeat angioplasty of the left anterior descending coronary artery due to restenosis. (kardiologiapolska.pl)
  • Coronary angioplasty is widely accepted method of myocardium revascularisation. (kardiologiapolska.pl)
  • We present a case of a 79-year-old female with repeat angioplasty done 6 times to the left anterior descending artery due to acute coronary syndromes in a 4-year period. (kardiologiapolska.pl)
  • Patients without control angiogram (n=181), patients with only coronary balloon angioplasty (n=46), and stent implantation to bypass graft veins (n=20) were excluded from the study. (journalmeddbu.com)
  • It is well known that coronary artery angioplasty and stenting are both associated with local vascular and systemic inflammation (1-4), which in turn correlate with increased restenosis after percutaneous coronary interventions (PCI) (5-7). (scielo.br)
  • However, the nature of the inflammatory response to coronary artery stenting is different from that associated with balloon angioplasty, and the specific biological response to stent injury is strongly associated with intimal smooth muscle cell migration/proliferation that culminates in in-stent restenosis (ISR) (8). (scielo.br)
  • Percutaneous transluminal coronary angioplasty is a medical procedure whose purpose is to increase blood flow through an artery. (google.ca)
  • Percutaneous transluminal coronary angioplasty is the predominant treatment for coronary vessel stenosis. (google.ca)
  • A limitation associated with percutaneous transluminal coronary angioplasty is the abrupt closure of the vessel which may occur immediately after the procedure and restenosis which occurs gradually following the procedure. (google.ca)
  • Restenosis after percutaneous transluminal coronary angioplasty is a more gradual process initiated by vascular injury. (google.ca)
  • Quantitative coronary angiography was performed before PTCA and after PTCA and at follow-up. (ahajournals.org)
  • Reference diameter, minimal lumen diameter, and percent diameter stenosis (DS) were measured by quantitative coronary angiography. (ahajournals.org)
  • Objective To evaluate the performance of Dual source CT coronary angiography (DSCT-CA) in the detection of in-stent restenosis (≥50% luminal narrowing) in symptomatic patients referred for conventional angiography (CA). (bmj.com)
  • The patients received coronary angiography (CAG) at the onset of the ACS and nine months after that, and also received an exercise tolerance test (ETT) at the start of the CR program and several days before receiving a follow-up CAG. (biomedsearch.com)
  • 2 Coronary angiography (CAG) has become the leading method in detecting restenosis following PCI, but it is an expensive and invasive diagnostic tool. (biomedsearch.com)
  • Quantitative coronary angiography (QCA) was performed at study entry and again at 6-month follow-up. (diabetesjournals.org)
  • 4.Endpoints 4.1.Primary Endpoint The primary end-point is defined by: - In-stent late luminal loss after 9 months of implant procedure 4.2.Secondary Endpoint The secondary end-points are defined by: - Binary restenosis (defined as in-segment stenosis of at least 50 percent on follow-up angiography) - Incidence of major adverse cardiac events (MACE) within discharge, 30 days, 6 and 12 months after implant procedure. (centerwatch.com)
  • Clinical indications for coronary angiography were based on the stress treadmill test and symptoms. (termedia.pl)
  • Patients with a significantly positive stress treadmill with ST depressions more than 4 mm and with a low exercise tolerance (less than about 4 MET) were qualified for coronary angiography. (termedia.pl)
  • Objective Systematic investigation of restenosis after percutaneous coronary intervention (PCI) with bare metal stents (BMS) or first or second generation drug eluting stents (DES) in large scale, broadly inclusive patient populations undergoing follow-up angiography represents a gap in our scientific knowledge. (bmj.com)
  • Methods All patients undergoing successful implantation of coronary stents for de novo lesions from 1998 to 2009 and follow-up angiography at 6-8 months at two centres in Munich, Germany were eligible for inclusion. (bmj.com)
  • The incidence of restenosis, defined as diameter stenosis ≥50% in the in-segment area at follow-up angiography, and its predictors were evaluated. (bmj.com)
  • In our dataset of patients who had clinically driven repeat angiography after single vessel percutaneous coronary intervention (243 patients, 277 lesions), stents were initially "over - expanded" above nominal size in 99% of cases, using manufacturers' compliance charts as a size reference, a validated, real-world practice (3) . (onlinejacc.org)
  • All patients underwent coronary angiography after one-year follow-up. (biomedsearch.com)
  • In a group of 11 patients with restenosis confirmed in the coronary angiography, one-year follow-up DSE was found positive in 9 patients (80% test sensitivity) but in two cases results were false negative. (biomedsearch.com)
  • We measured plasma OPN levels in 90 patients with CAD undergoing elective coronary angiography for suspected restenosis. (ahajournals.org)
  • Balloon inflations were repeated until a satisfactory result was achieved in on-line quantitative coronary angiography or ICUS fulfilling the OPTICUS study criteria. (uni-muenchen.de)
  • A subsequent coronary angiography was performed 6-9 months later for suspected restenosis for patients (N=273) who underwent coronary stent implantation. (ahajournals.org)
  • In-stent restenosis was evaluated by means of quantitative angiography. (ahajournals.org)
  • The present study enrolled 2312 patients with type 2 diabetes mellitus who underwent percutaneous coronary intervention from January 2013 to December 2014 and who were followed up by angiography. (springer.com)
  • In 01/2017, she had recurrence of her anginal equivalent, and underwent coronary and graft angiography, which showed recurrent ISR of her LCX Promus stents. (cathlabdigest.com)
  • She then underwent repeat coronary and graft angiography, which showed a CTO of her proximal LCX segment where brachytherapy had previously been administered. (cathlabdigest.com)
  • We seated a 7 Fr 90 cm Judkins right (JR) 4 guide in the right coronary artery (RCA) and an 8 Fr 100 cm extra backup (EBU) 4.0 guide in the left main coronary artery (LMCA), and performed dual angiography (Figure 1). (cathlabdigest.com)
  • The study comprised 126 male and female patients with stable angina pectoris, who underwent elective coronary stenting with DES and follow-up angiography within 6-12 months. (springermedizin.at)
  • METHODS: Total 153 patient was enrolled to the study who meet criteria for angiographic indication underwent coronary artery angiography. (minervamedica.it)
  • A similar subintimal crossing and crush technique of an in-stent restenotic lesion in the distal coronary artery has been reported by others, with continued patency documented on coronary angiography performed 9 months later. (invasivecardiology.com)
  • Baseline and 6-month follow-up quantitative coronary angiography was performed by an independent blinded core lab and all patients will be evaluated clinically for up to one year. (ovid.com)
  • Control angiography was performed in 477 of 565 patients (84.4%) with following restenosis rates in genotype subgroups: CC 29.0% vs GC/GG 22.6% (p = 0.33) in L162V, CC 29.9% vs TC/TT 24.6% (p = 0.24) in C161T and A/A 26.9% vs A/AA + AA/AA 35.0% (p = 0.14) in A(39526)AA polymorphisms. (cdc.gov)
  • We compared the morphological characteristics of ISR between first- and second-generation DESs using frequency domain optical coherence tomography (OCT)[email protected]*[email protected]#Patients who underwent follow-up coronary angiography (CAG) after first-generation (CYPHER™ and TAXUS™) and second-generation (Nobori®, PROMUS Element™, Resolute Integrity and XIENCE) DES implantations were examined. (bvsalud.org)
  • Of the 140 lesions, follow-up coronary angiography (CAG) was performed on 117 lesions (101 patients) and revealed 46 SES re-restenotic and 71 non-re-restenotic lesions. (nih.gov)
  • After approximately 2 years, the patient underwent coronary angiography for recurrent chest pain. (elsevier.com)
  • OBJECTIVES: To evaluate the diagnostic accuracy of Mehran’s in-stent restenosis (ISR) classification by coronary computed angiography (CCTA), with reference to invasive coronary angiography (ICA). (thepreparedminds.com)
  • CONCLUSIONS: Angiographic patterns of in-stent restenosis can be accurately classified by coronary computed angiography. (thepreparedminds.com)
  • The lesion length measured by CCTA is longer than that assessed by invasive coronary angiography. (thepreparedminds.com)
  • The primary outcome was either restenosis detected by new coronary angiography or angina with myocardial ischemia at the territory of the stented coronary artery. (biomedcentral.com)
  • Angiographic restenosis is defined as a 50% narrowing at the PCI site in follow-up angiography, while clinical restenosis is considered present when ischaemic symptoms are seen and/or an ischaemic functional test is positive in individuals with ≥ 50% stenosis of the target vessel [ 4 ]. (biomedcentral.com)
  • Drug-eluting stents (DES) are effective in reducing restenosis and the benefits are greatest in patients at the highest risk of target-vessel revascularization (TVR). (medindia.net)
  • Although DSCT-CA leads to frequent false positive findings in smaller stents (≤2.75mm), it reliably rules-out in-stent restenosis irrespective of stent size. (bmj.com)
  • The aim of the study is to assess the efficacy of the Paclitaxel-eluting PTCA - balloon catheter SeQuent® Please to treat in-stent restenoses (ISR) of various drug eluting stents in nativ. (bioportfolio.com)
  • Culotte stenting for coronary bifurcation lesions with 2nd and 3rd generation everolimus-eluting stents: the CELTIC Bifurcation Study. (bioportfolio.com)
  • We evaluated restenosis, stent thrombosis (ST) and mortality in the LAD as compared to the RCA and LCX according to stent type, bare metal (BMS) or drug-eluting stents (DES). (diva-portal.org)
  • The purpose of this study is to evaluate the clinical results of our series of symptomatic ostial VAS treated exclusively with tubular balloon expandable coronary stents. (clinicaltrials.gov)
  • This approach would present a more effective and economical alternative to the use of drug-eluting stents to reduce stent restenosis. (clinicaltrials.gov)
  • We investigated the incidence of angiographically proven restenosis and its predictors in patients undergoing PCI with stents. (bmj.com)
  • Their multivariate analysis identifying predictors of stent failure indicated that most risk factors could not be modified, for example, right coronary artery location, hinge motion at lesion position and long lesion length (requiring long/multiple stents). (onlinejacc.org)
  • They suggested that aggressive post-dilation of smaller stents is an operator-dependent procedural risk factor for stent fracture and hence restenosis, a potentially avoidable problem. (onlinejacc.org)
  • The practice of aggressive post-dilation of stents developed with evidence from early intravascular ultrasound studies showing that suboptimal stent expansion is common and predisposes to restenosis and stent thrombosis (4) . (onlinejacc.org)
  • This study evaluated the effect of lowering homocysteine on the rate of restenosis following PTCA with or without stents. (acc.org)
  • Molecular basis of restenosis and drug-eluting stents. (springermedizin.at)
  • If a patient develops restenosis after two or more layers of stents, radiation treatment (brachytherapy) is an excellent option for preventing another recurrence of blockage due to scar tissue. (beaumont.org)
  • This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. (elsevier.com)
  • While drug-eluting stents have improved outcomes after percutaneous coronary intervention, 4-14% of patients in modern clinical trials still develop symptomatic restenosis. (elsevier.com)
  • Novel approaches to treating restenosis include a number of ongoing trials comparing treatment strategies with currently available drug eluting stents, use of drug coated balloons, and interventional strategies to increase stent expansion. (elsevier.com)
  • Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. (semanticscholar.org)
  • Therefore, we investigated the influence of different conventional (Conv) and monoenergetic (MonoE) reconstructions from a SDLCT and a SPCCT on the delineation of soft-plaque-restenosis in coronary stents. (philips.com)
  • Artificial stenosis (~30HU) were implanted into 10 different coronary stents (diameter 3mm) embedded in plastic tubes filled with Iohexol-based contrast agent (~400HU). (philips.com)
  • SPCCT will have the potential to significantly improve the important but still challenging non-invasive evaluation of coronary stents and possible restenosis. (philips.com)
  • [email protected]#The pathophysiology and mechanism of in-stent restenosis (ISR) after implantation of second-generation drug-eluting stents (DESs) are not fully clear. (bvsalud.org)
  • The positive final guidance confirms the case for adopting the SeQuent Please drug-eluting balloon (B.Braun) for patients with restenosis following insertion of bare metal coronary artery stents. (cardiovascularnews.com)
  • The recommendations on SeQuent Please balloon catheter include that it should be considered for use in patients with in-stent restenosis in bare metal coronary artery stents, and in patients with other types of stent where there are clinical reasons to minimise how long clopidogrel treatment is used. (cardiovascularnews.com)
  • Drug-eluting stents to prevent stent thrombosis and restenosis. (nextbio.com)
  • Unless your risk factors change after stent placement, plaque will continue to build up in your coronary arteries, including in stents, which can lead to restenosis. (healthline.com)
  • Fortunately, according to the National Heart Lung and Blood Institute , IST develops in only about 1 percent of coronary artery stents. (healthline.com)
  • Hamid H, Coltart J. 'Miracle stents'-a future without restenosis. (ccrjournal.org)
  • Sirolimus- eluting stents versus standard stents in patients with stenosis in a native coronary artery. (ccrjournal.org)
  • Mechanisms and Patterns of Intravascular Ultrasound In-Stent Restenosis Among Bare Metal Stents and First- and Second- Generation Drug-Eluting Stents. (ccrjournal.org)
  • We aimed to confirm the effects of 3-month celecoxib in patients receiving drug-eluting stent (DES) implantation in the larger prospective, randomized trial.Methods and resultsPatients (n 909) treated for native coronary lesions were randomized into four groups: the control or the celecoxib group with stratification by stents: paclitaxel-eluting stent (PES) or zotarolimus-eluting stent (ZES). (elsevier.com)
  • Background-: Drug-eluting stents (DES) for percutaneous coronary intervention decrease the risk of restenosis compared with bare metal stents. (wustl.edu)
  • We studied the effect of oral sirolimus, administered to prevent and treat in-stent restenosis (ISR), on the variation of serum levels of inflammatory markers following coronary stenting with bare metal stents. (scielo.br)
  • All patients underwent elective coronary stent implantation in a stenosis of a major coronary vessel. (uni-muenchen.de)
  • The subgroups did not differ in regard to age, gender, extent of coronary artery disease, stenosis length, initial degree of stenosis or degree of stenosis after stent implantation. (uni-muenchen.de)
  • 50%) stenosis that was documented on a recent coronary angiogram. (acc.org)
  • Angiographic restenosis defined as a residual stenosis of (acc.org)
  • Significant restenosis was defined as ≤ 50% luminal diameter stenosis of a coronary segment with previous PTCA and was predicted on the basis of the occurrence of reversible perfusion defects in the corresponding territories. (eur.nl)
  • The overall sensitivity of 99Tcm-MIBI SPET for the diagnosis of significant coronary stenosis (including arteries without previous PTCA) on a patient basis was 79% (Cl = 67-92), the specificity 82% (Cl = 70-94) and accuracy 80% (Cl = 68-92). (eur.nl)
  • PURPOSE Balloon dilatation of coronary artery stenosis has become a standard treatment of atherosclerotic heart disease. (semanticscholar.org)
  • Angiographic restenosis occurred in 22 patients (55%) by visual estimates of stenosis. (bu.edu.eg)
  • High keV MonoE reconstructions are not recommended for coronary stent assessment with SPCCT or SDLCT due to impeded stenosis delineation. (philips.com)
  • Angiographic restenosis, defined as more than 50 percent luminal diameter stenosis was absent in 24 (54.5%, Group A) and present in 20 (45.5%, Group B) patients. (who.int)
  • When it happens in the heart's arteries (coronary arteries), it's called coronary artery stenosis. (healthline.com)
  • Restenosis ("re" + "stenosis") is when a part of the artery that was previously treated for blockage becomes narrow again. (healthline.com)
  • A DES helps prevent restenosis due to new tissue growth, but it doesn't affect the underlying condition that caused stenosis in the first place. (healthline.com)
  • Restenosis from underlying CAD takes longer to develop, and most often occurs a year or more after the original stenosis is treated. (healthline.com)
  • The purpose of the study was to identify the possible relationship between the +2238 T/C polymorphism and restenosis in coronary arteries stented due to the coronary artery disease (CAD). (muni.cz)
  • Furthermore, stenting of the native coronary arteries in diabetic patients is associated with a significantly higher in-stent restenosis rates up to 32-66%, regardless of the treatment modality for diabetes ( 3 , 7 ), resulting in a higher rate of morbidity and mortality compared with those for nondiabetic patients. (diabetesjournals.org)
  • Treatment of lesions in native coronary arteries requiring stenting. (clinicaltrials.gov)
  • Elevated levels of homocysteine and 2 polymorphisms of the MTHFR gene are not associated with restenosis after stenting in coronary arteries. (unboundmedicine.com)
  • A correlation found between contact allergy to stent material and restenosis of the coronary arteries. (lu.se)
  • Reversible perfusion defects occurred in 20 of 29 arteries with and in 4 of 17 arteries without restenosis. (eur.nl)
  • The sensitivity of dobutamine MIBI for the detection of restenosis in arteries with previous PTCA was 69% (Cl = 56-82), the specificity 76% (Cl = 64-89), the positive predictive value 83% (Cl = 73-94), the negative predictive value 59% (Cl = 45-73) and accuracy 72% (Cl = 59-85). (eur.nl)
  • The pathobiology of restenosis in stented arteries is largely related to neointimal hyperplasia, which is dependent upon several factors, such as a reduction in nitric oxide activity that determines endothelial dysfunction and oxidative stress. (elsevier.com)
  • Here, we present a case of a 63-year-old male who presented with in-stent restenosis of two coronary arteries simultaneously (mid circumflex and proximal ramus). (elsevier.com)
  • RESULTS: Restenosis occurred in 36 patients with occluded arteries (29%) versus 264 with nonoccluded arteries (23%, p = 0.177) by definition 1 and in 62 patients with occluded arteries (49%) versus 478 with nonoccluded arteries (42%, p = 0.119) by definition 2. (duke.edu)
  • These patients were at high risk for developing ISR, with 17 lesions in native coronary arteries (9 de novo and 8 ISR), without angina or documented ischemia. (scielo.br)
  • Methods: 50 patients with BMS restenosis (SVG and bifurcation lesions will be excluded) will be randomized into two treatment groups: SeQuent Please drug-eluting balloon dilatation (group I) versus implantation of an everolimus-eluting Xience V stent (group II). (bioportfolio.com)
  • Everolimus drug-eluting stent performance in patients with long coronary lesions: The multicenter Longprime registry. (bioportfolio.com)
  • To assess the efficacy and safety of the Xience Prime everolimus-eluting stent (EES) in long coronary lesions in a real-world population. (bioportfolio.com)
  • The rate of in-stent restenosis was significantly reduced in the rosiglitazone group compared with the control group (for stent lesions: 17.6 vs. 38.2%, P = 0.030). (diabetesjournals.org)
  • Background: Percutaneous coronary intervention (PCI) of lesions in the proximal left anterior descending coronary artery (LAD) may confer a worse prognosis compared with the proximal right coronary artery (RCA) and left circumflex coronary artery (LCX). (diva-portal.org)
  • Angiographic exclusion criteria were restenosis lesions, significant left main coronary artery disease, target lesions in a coronary bypass graft or in a vessel that was totally occluded, and perfusion grade of 0 or 1 as defined by the TIMI Investigators. (acc.org)
  • 12 Given the exceptionally high target lesion failure rates when adding a third layer of stent, and that drug-eluting or coated balloons are not yet available for coronary use in the United States, operators will often rely on methods of image-guided stent optimization and atherectomy to treat recurrent ISR lesions in segments that have been previously stented twice. (cathlabdigest.com)
  • Scoring balloons produce excellent acute results in the treatment of in-stent restenosis (ISR), fibro-calcific and bifurcation lesions but have not been shown to affect the restenosis rate. (ovid.com)
  • Restenosis increased significantly in left anterior descending artery (LAD) (73.7%) and in proximal segment (82.4%) lesions. (bu.edu.eg)
  • 83.3 & 75%) respectively There was significant increase in sensitivity, specificity and diagnostic accuracy of DSE for LAD lesions (85.7, 100 & 89.5%) respectively while there was significant decrease in sensitivity of left circumfier (LCX and right coronary artery (RCA) lesions (25 & 50%) respectively. (bu.edu.eg)
  • In two further chapters modified and new techniques in the treatment of coronary bifurcation lesions are discussed. (uu.nl)
  • Restenoisis resuts in recurrence of angina in 15 to 20% of patients and angiographic restenosis in 30 to 40 % of lesions dilated. (uthscsa.edu)
  • A recent research report showed that f rom 2006 to 2014, 65,443 patients underwent percutaneous coronary intervention (PCI) and 6,872 patients (10.5%) with 8,921 lesions were treated for in-stent restenosis ( ISR). (blogspot.co.uk)
  • Repeat revascularization for SES restenosis was performed in 113 patients with 140 lesions. (nih.gov)
  • In a clinical multicenter study, a mid-infrared, solid-state, pulsed-wave laser (holmium:YAG, 2.1 μm wavelength, 250-600 mJ/pulse, 5 Hz) was applied for revascularization of de novo and restenosis coronary lesions. (elsevier.com)
  • Restenosis lesions, known to be composed of smooth muscle proliferation, needed more laser energy for ablation than de novo lesions, which contain an atherosclerotic plaque (130 ± 123 pulses vs 109 ± 31, p = 0.001). (elsevier.com)
  • Procedure-related Q-wave myocardial infarction was significantly higher in patients with de novo lesions over patients with restenosis lesions (1.4 vs 0.2%, p = 0.05). (elsevier.com)
  • this led to their expanded use in more complex lesions and less selective populations, re-elevating the rates of restenosis. (biomedcentral.com)
  • Atherosclerotic lesions, which limit or obstruct coronary blood flow, are the major cause of ischemic heart disease. (google.ca)
  • Background: The optimal treatment of bare metal stent restenosis (implantation of a drug-eluting stent, simple balloon dilatation, CABG) is still not defined. (bioportfolio.com)
  • CONCLUSIONS -We demonstrated that treatment with rosiglitazone significantly reduces in-stent restenosis in diabetic patients with CAD who underwent coronary stent implantation. (diabetesjournals.org)
  • It has been reported that TZDs reduce neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes ( 17 - 19 ). (diabetesjournals.org)
  • Ninety-five patients with previously treated diabetes (oral hypoglycemic agents or insulin) who had recent acute myocardial infarction or stable or unstable angina and underwent coronary stent implantation at the Cardiovascular Center, Severance Hospital, Yonsei University College of Medicine, were recruited in this study. (diabetesjournals.org)
  • Data from rodent models suggest that TZDs limit intimal proliferation after vascular injury, and in clinical studies with type 2 diabetic coronary artery disease (CAD) patients, TZDs have been shown to reduce neointimal formation as well as restenosis after coronary stent implantation. (centerwatch.com)
  • Aim of the study is to evaluate the efficacy of pioglitazone in prevention of in-stent restenosis after successful implantation of a sirolimus-eluting coronary stent for treatment of de-novo "complex" coronary vessel disease in patients with T2DM and stable coronary artery disease. (centerwatch.com)
  • We included 2,178 consecutive patients with coronary artery disease who underwent intracoronary stent implantation, 789 (36.2%) with HPA-3a/a, 1,023 (47.0%) with HPA-3a/b, and 366 (16.8%) with HPA-3b/b genotype. (nih.gov)
  • Restenosis is the major adverse effect of coronary stent implantation. (centerwatch.com)
  • Drug-eluting stent has markedly reduced restenosis as compared with bare-metal stent, but restenosis is still the main cause of repeat coronary intervention after drug-eluting stent implantation. (centerwatch.com)
  • After coronary stent implantation, inflammatory reaction occurs in vessel wall and vascular smooth muscle cells proliferate. (centerwatch.com)
  • Recent publications have elucidated the hypothesis that the ACE gene polymorphism may influence the level of late luminal loss after coronary stent implantation. (uni-muenchen.de)
  • In this multicenter study, we therefore tested the relationship between the ACE gene polymorphism and the restenosis rate after coronary stent implantation. (uni-muenchen.de)
  • Predictors of ScR match those of metallic stent restenosis, and the implantation technique used at index appears to play an important role. (onlinejacc.org)
  • Methods Actually, few and conflicting data are available about the management of in-stent restenosis (ISR) after DES implantation. (ovid.com)
  • The aim of this study was to assess CD45-positive platelets (CD45+ platelets) involvement in restenosis development after drug-eluting stent (DES) implantation in patients with stable coronary artery disease (CAD). (springermedizin.at)
  • We have also constructed a logit regression model for prognosis of restenosis occurrence after DES implantation. (springermedizin.at)
  • The acquired data indicate the presence of a close relationship between circulating CD45+ platelets and restenosis development after DES implantation in patients with stable CAD. (springermedizin.at)
  • All patients have history undergone for coronary stent implantation 3 to 9 months ago. (minervamedica.it)
  • Predictive factors of re-restenosis after repeated sirolimus-eluting stent implantation for SES restenosis and clinical outcomes after percutaneous. (nih.gov)
  • In this study, we analyzed clinical and angiographic variables that might be related with SES re-restenosis and variables related with re-restenosis after repeat SES implantation for SES restenosis. (nih.gov)
  • A retrospective study was conducted on 924 consecutive patients undergoing percutaneous coronary intervention (PCI) for DES implantation and who were followed-up by cardiac coronarography within 1 year. (ccrjournal.org)
  • The purpose of this study was to investigate the effects of perfluorocarbon gas microbubble carrier (PGMC)-based systemic delivery of AVI-4126 on expression of the c-myc in vascular tissue and restenosis after stent implantation. (nebraska.edu)
  • Conclusions Patients with first- and second-generation DES restenosis, both EES and ZES implantation were effective and safe in reducing neointima volume and late loss with a comparable rate of MACEs independent of cardiovascular risk factors. (elsevier.com)
  • The objective of this study was to evaluate circulating EPC before and after percutaneous coronary intervention (PCI) with stent implantation and their associations with coronary restenosis and adverse cardiovascular events. (biomedcentral.com)
  • The main objective of the study is to determine whether PCI for in-stent restenosis with a drug eluting balloon is angiographically non-inferior to PCI with a drug eluting stent at 6 month. (bioportfolio.com)
  • Angiographic and clinical performance of a paclitaxel coated balloon compared to a 2nd generation sirolimus eluting stent in patients with in-stent restenosis- the BIOLUX randomized controlled trial. (bioportfolio.com)
  • We present a case of a left circumflex (LCX) coronary artery CTO due to ISR of a double layer of stent, both of which were under-deployed, utilizing a novel cutting balloon (Wolverine Cutting Balloon, Boston Scientific) after oversized noncompliant balloon inflation and both laser and rotational atherectomy failed to provide adequate lumen gain. (cathlabdigest.com)
  • The most common treatment of restenosis is placement of another drug-coated stent inside the old stent, since this usually works better than balloon alone. (beaumont.org)
  • This positive guidance advises the NHS that SeQuent Please balloon catheter should be considered for use in patients with in-stent restenosis in specific circumstances. (cardiovascularnews.com)
  • The evidence considered indicates that SeQuent Please balloon catheter may benefit patients and the NHS in the long term by reducing the number of cases requiring further treatment for restenosis. (cardiovascularnews.com)
  • 25%, the greater the over-expansion, the less the percent angiographic restenosis (p = 0.02). (onlinejacc.org)
  • This review concluded that adding cilostazol to dual antiplatelet therapy (aspirin and thienopyridine) reduced angiographic restenosis at six months after coronary artery stenting, without affecting major adverse cardiac events or bleeding. (york.ac.uk)
  • Eligible trials were also required to report data on angiographic restenosis. (york.ac.uk)
  • The primary endpoint was the incidence of angiographic restenosis at six months (defined as 50% or more narrowing of the reference lumen diameter). (york.ac.uk)
  • The addition of cilostazol to standard dual antiplatelet therapy reduced angiographic restenosis and increased minimal luminal diameter at six months after coronary artery stenting, without affecting major adverse cardiac events or bleeding. (york.ac.uk)
  • Angiographic restenosis was defined as 50% or more luminal narrowing in the target lesion. (slideplayer.com)
  • Study primary end-point are late-loss at 9 months.Secondary end-point include binary restenosis MACE at 1, 9 and 12 month, stent thrombosis at 12 months. (centerwatch.com)
  • We designed this prospective study to assess whether patients with the human platelet antigen (HPA)-3 polymorphism of GPIIb are more susceptible to developing thrombosis and restenosis after coronary stent placement. (nih.gov)
  • We conclude that the HPA-3 polymorphism of platelet GPIIb is not associated with an increase in the risk of thrombosis and restenosis over 1 year after coronary stent placement. (nih.gov)
  • Byrne R, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? (ccrjournal.org)
  • The purpose of this prospective, randomized 9-month intracoronary ultrasound (IVUS) and 3-year clinical follow-up study was to compare the effects of EESs and ZESs on neointima volume and major adverse cardiovascular events (MACEs) such as death, myocardial infarction (MI), target lesion revascularization (TLR) and stent thrombosis in DES restenosis patients. (elsevier.com)
  • Although endovascular stenting has been used as an interventional therapy to treat cardio- and cerebro-vascular diseases, it is associated with recurrent vascular diseases following stent thrombosis and in-stent restenosis. (elsevier.com)
  • A reduction in DES use among patients at low risk for restenosis was projected to be associated with substantial costs savings with only a small increase in TVR events," the authors note. (medindia.net)
  • No previous studies comparing the health status outcomes of PCI and CABG have examined differences in these outcomes as a function of patients' preprocedural risk for restenosis. (unboundmedicine.com)
  • We examined the health status outcomes, using the Seattle Angina Questionnaire (SAQ), among 1459 consecutive patients (1027 treated with PCI and 432, with CABG), stratified by their risk for restenosis. (unboundmedicine.com)
  • In multivariable-adjusted, linear regression analyses, no differences in 1-year angina or quality of life were observed among the 37.4% of patients at low risk for restenosis. (unboundmedicine.com)
  • The risk for restenosis was threefold increased. (lu.se)
  • The risk for restenosis was threefold increased when the patient was gold allergic and stented with a gold-plated stent. (lu.se)
  • However, data derived from smaller studies indicates that coronary collaterals may increase the risk for restenosis after percutaneous coronary interventions. (biomedcentral.com)
  • The purpose of this systematic review and meta-analysis of observational studies was to explore the impact of the collateral circulation on the risk for restenosis. (biomedcentral.com)
  • The purpose of this systematic review and meta-analysis was to integrate all available data in order to provide a clearer understanding of the impact of the coronary collateral on the risk for restenosis following PCI. (biomedcentral.com)
  • However, they are costlier, require prolonged dual antiplatelet therapy, and provide the most benefit in patients at highest risk for restenosis. (wustl.edu)
  • Conclusions -Cilostazol significantly reduces restenosis and target lesion revascularization rates after successful PTCA. (ahajournals.org)
  • Treatment lowered homocysteine levels from 11.1 +/- 4.3μm/L to 7.2 +/- 2.4 μm/L. The rate of restenosis was significantly lower on treatment (19.6% vs 37.6%, p = 0.01) as was the need for target vessel revascularization (10.8% vs. 22.3%, p = 0.047). (acc.org)
  • Treatment with a combination of folic acid, vitamin B-12, and pyridoxine significantly reduces the rate of restenosis following PTCA and the need for target vessel revascularization after PCI. (acc.org)
  • Percutaneous coronary intervention (PCI) is an effective technique for coronary revascularization but a considerable number of patients develop restenosis after stenting. (ahajournals.org)
  • This has provided the impetus for the development of newer alternative forms of coronary revascularization such as coronary stenting (CS). (onlinejacc.org)
  • Restenosis is a reparative response to arterial injury occurring with percutaneous coronary revascularization. (elsevier.com)
  • The proportion of patients undergoing revascularization for restenosis increased 0.28% per year [1] . (blogspot.co.uk)
  • Major adverse cardiac events (MACE) at 2 years were found in 44 patients (43.5%), and target lesion revascularization (TLR) was performed in 33.7% of patients after SES restenosis. (nih.gov)
  • 5 ] In-stent restenosis (ISR), defined as >50% narrowing of stent lumen or coronary artery 5 mm adjacent to stent edges, is a restricting complication of PCI leading to repeat revascularization. (journalmeddbu.com)
  • Usefulness of early dobutamine stress echocardiography for the assessment of risk of restenosis after percutaneous coronary interventions. (biomedsearch.com)
  • BACKGROUND: The increasing role of percutaneous coronary interventions (PCI) in the treatment of coronary artery disease and relatively high restenosis rate following PCI require the introduction of available, easy to perform and cost-effective tests that would enable detection of restenosis after PTCA and identification of patients at particularly high risk of restenosis. (biomedsearch.com)
  • Previous comparisons of percutaneous coronary interventions (PCIs) and coronary artery bypass graft (CABG) surgery have demonstrated similar survival but have also generally found better health status outcomes (symptoms, function, and quality of life) with CABG. (unboundmedicine.com)
  • Background Neointimal hyperplasia after percutaneous coronary interventions is one of the key components of the restenotic process. (onlinejacc.org)
  • Coronary equipments are ideal for ostial VAS, considering the size of the artery and location of the lesion. (clinicaltrials.gov)
  • Predictors of restenosis were small vessel size, increased stented length, complex lesion morphology, diabetes mellitus, and prior bypass surgery. (bmj.com)
  • To determine whether diabetic patients, when compared with nondiabetic patients, have a higher incidence of restenosis after coronary stenting, and, if so, whether restenosis is attributable to lesion or procedural differences or to a greater biologic tendency for late loss of minimum diameter in diabetic patients. (annals.org)
  • 6-9 Additionally, the treatment of in-stent restenosis (ISR) CTOs has been identified as an independent predictor of target lesion failure after CTO PCI and increased major adverse cardiovascular events (MACE) compared to CTOs that do not involve ISR. (cathlabdigest.com)
  • In-stent restenosis was observed in 73 and remaining of 80 patients revealed no critical lesion in stent on angiographic evaluation. (minervamedica.it)
  • Multivariate statistical significance: negative correlation was found between in-stent restenosis and renin-angiotensin-system (RAS) blocker usage (P=0.040) and right coronary artery (RCA) lesion interventions (P=0.018). (minervamedica.it)
  • Secondary endpoints were death, myocardial infarction and/or target lesion revascularisation at 12 months, and clinical restenosis. (cdc.gov)
  • Analysis of data was undertaken to document laser success, complications, and restenosis rate and to define whether the type of lesion treated had an effect on laser success and related complications. (elsevier.com)
  • METHODS AND RESULTS: Homocysteine levels and MTHFR genotypes were determined in 800 consecutive patients treated with coronary artery stenting. (unboundmedicine.com)
  • METHODS: Thirty-nine patients with a single coronary vessel disease after PCI were enrolled in this study. (biomedsearch.com)
  • Methods: As a substudy of the optimization with intracoronary, ultrasound (ICUS) to reduce stent restenosis (OPTICUS) study, we analyzed ACE serum levels and the ACE gene polymorphism in 154 patients at 9 different centers. (uni-muenchen.de)
  • Methods A total of 657 consecutive patients (age 63 ± 12 years, 79% men, 21% diabetics, 67% acute coronary syndrome) who received a total of 883 BRS for the treatment of coronary artery stenoses between May 2012 and January 2015 were enrolled in a retrospective registry. (onlinejacc.org)
  • Methods and Results-: Preprocedural clinical and angiographic data from 27 107 percutaneous coronary intervention hospitalizations between October 1, 2004, and September 30, 2007, in Massachusetts were used to develop prediction models for TVR at 1 year. (wustl.edu)
  • The study group consisted of 60 consecutive patients (10 women and 50 men, average age 58.9 ±10.4 years) with stable coronary artery disease who underwent PCI. (termedia.pl)
  • For the subgroup of patients with stable coronary artery disease (CAD), the RR for restenosis with 'good collaterals' was 1.64 (95% CI 1.14 to 2.35) compared to 'poor collaterals' ( P = 0.008). (biomedcentral.com)
  • Percutaneous coronary intervention (PCI) has been used to treat coronary artery disease (CAD). (biomedsearch.com)
  • OBJECTIVE -Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. (diabetesjournals.org)
  • Coronary artery disease (CAD) secondary to atherosclerosis is the leading cause of death in patients with type 2 diabetes ( 1 ). (diabetesjournals.org)
  • Percutaneous coronary intervention (PCI) is widely used in treatment of coronary artery disease (CAD). (termedia.pl)
  • We investigated the influence of elevated homocysteine plasma levels and 2 polymorphisms, 677C/T and 1298A/C, of the methylenetetrahydrofolate reductase (MTHFR) gene on the risk of restenosis after stenting in patients with symptomatic coronary artery disease. (unboundmedicine.com)
  • Two hundred twenty consecutive patients with coronary artery disease who were referred for placement of a Palmaz-Schatz stent in either a native coronary artery or a saphenous vein graft. (annals.org)
  • 1,2 Recently, we reported plasma OPN levels to be high in patients with coronary artery disease (CAD) and to correlate with the severity of CAD. (ahajournals.org)
  • Coronary artery disease (CAD) represents the most important cause of sudden cardiac death. (ahajournals.org)
  • This study evaluateed the polymorphisms of the genes encoding key RAS components including angiotensinogen (AGT), angiotensin converting enzyme (ACE) and angiotensin type 1a (AT1a) receptor in relation to severity of coronary artery disease and in-stent restenosis after coronary stenting. (ahajournals.org)
  • Diabetic patients often have hypertriglyceridemia with elevated levels of VLDL cholesterol but normal levels of low-density lipoprotein cholesterol (LDL-C). The aim of the present study was to elucidate the potential role of remnant lipoproteins-induced atherosclerosis in the occurrence and development of in-stent restenosis (ISR) in diabetic patients with coronary artery disease. (springer.com)
  • Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. (semanticscholar.org)
  • C oronary in-stent is the most common treatment in coronary heart disease (CHD). (blogspot.co.uk)
  • Typically these are the symptoms of coronary artery disease (CAD) , such as chest pain ( angina ) and shortness of breath. (healthline.com)
  • The risk of restenosis continues until the risk factors for heart disease are reduced. (healthline.com)
  • In-Stent Restenosis (ISR) remains a significant problem for the treatment of coronary artery disease (CAD). (ccrjournal.org)
  • Matta A, Moussallem N. Evolution of the prevalence of angiographically significant coronary artery disease in lebanese population referred to cardiac catheterization. (ccrjournal.org)
  • Significant predictors of TVR included prior percutaneous coronary intervention, emergency or salvage percutaneous coronary intervention, prior coronary bypass surgery, peripheral vascular disease, diabetes mellitus, and angiographic characteristics. (wustl.edu)
  • If our hypothesis is confirmed, the treatment of in-stent restenosis with external radiation could substantially simplify the treatment of this disease. (elsevier.com)
  • A total of 1340 patients with 1465 stenoses presented with symptomatic coronary artery disease. (elsevier.com)
  • Percutaneous coronary intervention (PCI) is currently one of the cornerstones of the treatment of coronary artery disease [ 1 ], at least in part due to the lower immediate morbidity and mortality rates in comparison to coronary artery bypass grafting [ 2 ]. (biomedcentral.com)
  • This chapter summarizes the current knowledge about the relationships between job stress and heart diseases, particularly coronary heart disease (CHD). (springer.com)
  • Job strain and risk of acute recurrent coronary heart disease events. (springer.com)
  • Exhaustion and coronary heart disease: The history of a scientific quest. (springer.com)
  • The association between 'vital exhaustion' and past, present and future coronary heart disease. (springer.com)
  • Genetic polymorphisms of RAS are not associated with in-stent restenosis after coronary stenting. (ahajournals.org)
  • Clinical, angiographic, and biochemical factors associated with in-stent restenosis were retrospectively analyzed in patients undergoing percutaneous coronary intervention. (journalmeddbu.com)
  • We designed a prospective, randomized, controlled study to verify the hypothesis that rosiglitazone, another member of the TZD class, reduces the rate of restenosis in type 2 diabetic patients who have undergone coronary stenting. (diabetesjournals.org)
  • Despite the use of Drug eluting stent (DES), the rate of restenosis remains 7% to 16% in diabetic patients, making it a challenging problem in interventional cardiology. (centerwatch.com)
  • however, it may well require a combination of therapies to decrease the rate of restenosis. (uthscsa.edu)
  • Many studies have shown that hyperinsulinemia and insulin resistance increase neointimal index measured six months after coronary stenting, and that insulin- sensitizers have beneficial effects by decreasing the rate of restenosis. (elsevier.com)
  • METHOD: Subjects of this research were patients who participated in a cardiac rehabilitation (CR) program as six to eight weeks of a hospital-based program after receiving PCI to treat acute coronary syndrome (ACS). (biomedsearch.com)
  • Patients with acute coronary syndromes or creatinine >1.8mg/dl were excluded. (acc.org)
  • Patients with acute coronary syndrome were excluded. (ahajournals.org)
  • A Meta-analysis on 52 trials (4905 patients), the result showed at the end of at least 3 months' follow up, Chinese herb medicine could significantly reduce restenosis rate, cardiac mortality, recurrence rate of angina, acute myocardial infarction, numbers of repeat PCI, and numbers of coronary artery bypass graft [2] . (blogspot.co.uk)
  • Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. (nih.gov)
  • Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial. (nih.gov)
  • Platelets play a pivotal role in the pathogenesis of acute coronary syndrome (ACS) and acute and chronic complications following percutaneous coronary intervention (PCI). (biomedcentral.com)
  • Secondary outcomes were angina without demonstrable myocardial ischemia, acute coronary syndrome or all-cause death. (biomedcentral.com)
  • 5 Although some platelet aggregation inhibitors reportedly reduce restenosis, attempts to replicate these findings have failed in clinical studies. (ahajournals.org)
  • Although many pharmacological therapies, such as conventional antiplatelet drugs, anticoagulants, and the like, have been investigated in an attempt to reduce restenosis, the majority of trials have been disappointing ( 8 - 11 ). (diabetesjournals.org)
  • VISION(tm) and/or MINI-VISION(tm)) stent and pharmacologic therapy with the oral PPAR-gamma agonist rosiglitazone will significantly reduce restenosis after intracoronary stenting in type 2 diabetic patients. (clinicaltrials.gov)
  • In-stent restenosis is less developed after RCA interventions and taking drug of RAS blockages. (minervamedica.it)
  • A potential application of molecular therapy with antisense oligonucleotides is the prevention or treatment of restenosis after coronary interventions (1,2) . (onlinejacc.org)
  • We report the case of a patient with ITP who underwent three separate coronary interventions. (biomedcentral.com)
  • Targeted eNOS Gene Delivery with Lipopolyplexes for the Treatment of Coronary Restenosis Student: Luis Brito Department: Pharmaceutical Sciences Advisor: Mansoor Amiji Abstract The main thrust of this research is to develop gene therapy strategy. (northeastern.edu)
  • The mean follow-up interval for this subgroup was 30.5 months with a 22.4% cross-over rate to coronary bypass surgery, a 4.1% incidence rate of myocardial infarction and a 2% cardiac mortality rate. (nih.gov)
  • The incidence of stent restenosis was 37.3% in HPA-3a/a, 36.2% in HPA-3a/b, and 34.6% in HPA-3b/b patients (p = 0.724). (nih.gov)
  • (1) that described the incidence of the risk factors for stent fracture and restenosis. (onlinejacc.org)
  • After arterial injury produced by stent placement, diabetic patients have a significantly greater incidence of restenosis because of greater late loss at the treatment site. (annals.org)
  • Objectives The aim of this study was to describe the incidence and clinical characteristics, including intracoronary imaging features, of clinical restenosis in bioresorbable coronary scaffolds (BRS). (onlinejacc.org)
  • Treatment aims to relieve angina symptoms, reduce the risk of symptoms recurring and the incidence of restenosis. (cardiovascularnews.com)
  • Benefits of trimetazidine on the incidence of stent restenosis after percutaneous coronary intervention. (slideplayer.com)
  • In conclusion, the incidence of MACE and TLR was relatively high in patients with SES restenosis, but the placement of another SES on larger-diameter vessels may be an effective strategy for the second PCI. (nih.gov)
  • Conclusions This study demonstrated that intramural delivery of advanced c-myc neutrally charged antisense morpholino compound completely inhibits c-myc expression and dramatically reduces neointimal formation in a dose dependent fashion in a porcine coronary stent restenosis model, while allowing for complete vascular healing. (onlinejacc.org)
  • Twenty-six porcine coronary artery segments in 24 pigs were subjected to deep arterial injury with use of over-expanded, percutaneously delivered tantalum wire coils. (elsevier.com)
  • 05). Conclusion: In the porcine coronary stent model, systemic targeted delivery of AVI-4126 using PGMC carrier significantly inhibited neointimal formation. (nebraska.edu)
  • Conclusions: Following proximal coronary artery intervention restenosis was more frequent in the LAD than in the LCX. (diva-portal.org)
  • CONCLUSIONS: DSE is highly sensitive and specific in prediction and detection of restenosis after PCI. (biomedsearch.com)
  • CONCLUSIONS: We found a correlation between contact allergy to gold, gold-stent, and restenosis. (lu.se)
  • Conclusions- Allele-dependent transcriptional regulation of CCNB1 associated with rs350099, rs350104, and rs164390 affects the risk of in-stent restenosis. (ahajournals.org)
  • Each of these effects is an important target to prevent or treat atherosclerosis and restenosis. (diabetesjournals.org)
  • Severity of coronary atherosclerosis was assessed by angiographic Gensini score. (ahajournals.org)
  • Atherosclerosis can also cause restenosis. (healthline.com)
  • Further, the authors searched for clinical and procedural predictors of scaffold restenosis (ScR) and report on the clinical outcomes after treatment of ScR in a cohort of consecutive all-comer patients. (onlinejacc.org)
  • In Coronary Artery Restenosis: Causes, Treatment and Clinical Outcomes (pp. 263-283). (elsevier.com)
  • We also assessed clinical outcomes at 2-year follow-up after percutaneous coronary intervention (PCI) for SES restenosis. (nih.gov)
  • Since further knowledge of the influence of EPCs on restenosis might help identify patients at higher risk of restenosis or future events [ 12 ], this study aimed to evaluate EPC counts before and after PCI and the associations between EPC numbers and both restenosis and clinical outcomes. (biomedcentral.com)
  • Objective-This study aimed to determine whether the plasma levels of matrix metalloproteinase-9 (MMP-9) or tissue inhibitor of metalloproteinases-1 (TIMP-1) were altered in patients with a history of symptomatic in-stent restenosis (ISR). (semanticscholar.org)
  • Among these predictors, diabetes mellitus, current smoking, stent diameter and length, and age have been shown to stimulate restenosis, while trimetazidine has been shown to prevent restenosis. (slideplayer.com)
  • Similar to the results of other studies, we found that age, diabetes mellitus, current smoking, mean stent length, and mean stent diameter were also associated with stent restenosis. (slideplayer.com)
  • The clot usually blocks the entire coronary artery, so no blood can get to the part of the heart it supplies, causing a heart attack ( myocardial infarction ). (healthline.com)
  • The Predictive Value of ΣΔST/ΔHR Index for Restenosis after Percutaneous Coronary Intervention. (biomedsearch.com)
  • The need for restenosis-driven reintervention (clinical restenosis) was 18.8% in subjects with low homocysteine concentrations and 19.0% in subjects with high homocysteine concentrations during the first year after the intervention (P=0.93). (unboundmedicine.com)
  • TY - JOUR T1 - Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery bypass graft surgery. (unboundmedicine.com)
  • 3 However, no association between plasma OPN levels and restenosis after percutaneous coronary intervention (PCI) has yet been demonstrated. (ahajournals.org)
  • The risk of restenosis after percutaneous coronary intervention (PCI) is increased in patients with good coronary collateralization. (biomedcentral.com)
  • In-stent restenosis is an important factor for successful underwent percutaneous coronary intervention (PCI). (springer.com)
  • Since publication of the hybrid algorithm for crossing coronary chronic total occlusions (CTO), use of the algorithm has been associated with increased CTO percutaneous coronary intervention (PCI) adoption, procedural efficiency, and success rates. (cathlabdigest.com)
  • Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) of in-stent occlusions can be challenging. (invasivecardiology.com)
  • Background- The development of diagnostic tools to assess restenosis risk after stent deployment may enable the intervention to be tailored to the individual patient, for example, by targeting the use of drug-eluting stent to high-risk patients, with the goal of improving safety and reducing costs. (ahajournals.org)
  • While no single technology is likely to eliminate restenosis, the combination of these prevention and treatment strategies promises to improve the long-term outcomes of percutaneous coronary intervention. (elsevier.com)
  • A total of 150 patients treated with percutaneous coronary intervention (PCI) were divided into the ISR group and non-ISR group. (cdc.gov)
  • Subsequently the percentage of patients with diabetes subjected to revascularisation, i.e. either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) also rises rapidly. (biomedcentral.com)
  • The UK National Institute for Health and Clinical Excellence (NICE) issued its first medical technology guidance which supports the use of a device used in coronary artery intervention on 1 December 2010. (cardiovascularnews.com)
  • 2. Zheng GH.Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention. (blogspot.co.uk)
  • Percutaneous coronary intervention (PCI) is the most commonly preferred approach in most patients. (journalmeddbu.com)
  • Posted in Computed Tomography and tagged Conventional Percutaneous Coronary Intervention (CPCI) , Diagnostic Accuracy , In-Stent Restenosis (ISR) , Mehran’s Classification . (thepreparedminds.com)
  • Subsequent insights from intracoronary ultrasound studies in humans have demonstrated different mechanisms of restenosis after BA or after CS: although chronic remodeling (vessel constriction) is the major mechanism of restenosis after BA [9] , neointimal thickening is the major mechanism of restenosis after CS, as the stent prevents the remodeling process [10] . (onlinejacc.org)
  • She then underwent single-vessel coronary artery bypass graft surgery in 2009 for recurrent ISR of a stent in the proximal LAD. (cathlabdigest.com)
  • This study was thus performed to determine the relation between severity of vessel wall injury and the thickness of resulting neointimal proliferation in a porcine model of coronary restenosis. (elsevier.com)
  • In China, Chinese herbal medicines are widely used for preventing restenosis after stent placement. (blogspot.co.uk)
  • Restenosis, with or without stent placement, typically shows up between three and six months after the artery is reopened. (healthline.com)
  • Coronary brachytherapy is a special procedure using radiation therapy inside a stent to prevent recurrent blockage (restenosis). (beaumont.org)
  • Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction. (selfdecode.com)
  • We present here a case of a patient with ITP who experienced recurrent ACS and restenosis after PCI and we discuss the management strategies, including antiplatelet therapy. (biomedcentral.com)
  • Evaluation of soft-plaque-restenosis can be significantly improved by using conventional and low keV MonoE reconstructions of future SPCCT. (philips.com)
  • Tobacco use was significantly more frequent among patients with in-stent restenosis. (journalmeddbu.com)
  • Recently, drug-eluting balloons (DEB) were proposed as a new treatment strategy for bare metal stent restenosis. (bioportfolio.com)
  • Assessment of the coronary collateral circulation before PCI may be useful for risk stratification and for the choice of antiproliferative measures (drug-eluting stent instead bare-metal stent, cilostazol). (biomedcentral.com)
  • Patients at four clinical sites in Germany and one in Brazil with ISR of coronary bare metal stent (BMS) were randomized 1:1 to treatment with either a drug-coated or uncoated SB. (ovid.com)
  • In-stent restenosis occurred in 26.6% of the patients with drug-eluting stent and 36.5% of the patients with bare-metal stent implanted. (journalmeddbu.com)
  • 7 Panda et al 2 showed plasma OPN levels in 13 patients undergoing coronary atherectomy to be elevated after atherectomy, and they remained high for at least 4 weeks. (ahajournals.org)
  • Clinical study showed it can effectively prevent restenosis after PCI in combination with conventional western medical treatment. (blogspot.co.uk)
  • Delivery of rapamycin locally, particularly from an intravascular stent, directly from micropores in the stent body or mixed or bound to a polymer coating applied on stent, to inhibit neointimal tissue proliferation and thereby prevent restenosis. (google.ca)
  • The present study aimed to determine the effect of cilostazol on restenosis after PTCA. (ahajournals.org)
  • 12 13 In our previous study with directional coronary atherectomy (DCA) and intravascular ultrasound, we demonstrated that cilostazol has the potential to decrease restenosis by controlling intimal proliferation after PTCA in humans. (ahajournals.org)
  • 14 On the basis of these encouraging results, the present study aimed to confirm the inhibitory effect of cilostazol on restenosis after PTCA. (ahajournals.org)
  • There is an association between homocysteine levels and restenosis after PTCA. (acc.org)
  • It is concluded that dobutamine 99Tcm-MIBI SPET is a useful method for the detection of restenosis after PTCA in patients unable to perform an exercise stress test. (eur.nl)
  • We previously reported that cilostazol, a platelet aggregation inhibitor, inhibited intimal proliferation after directional coronary atherectomy and reduced the restenosis rate in humans. (ahajournals.org)
  • 2 However, neointimal proliferation caused primarily by smooth muscle cell (SMC) growth is a major mechanism of restenosis. (ahajournals.org)
  • Moreover, TZDs inhibit VSMC proliferation and migration, 2 critical processes in neointimal formation after coronary stenting. (centerwatch.com)
  • OPN may play a role in the development of restenosis associated with neointimal proliferation. (ahajournals.org)
  • We aimed to investigate the association between urotensin II (U-II) and in-stent restenosis after coronary stenting, which causes endothelial and muscle proliferation and accumulation of collagen. (minervamedica.it)
  • The CCNB1 gene (encoding cyclin B1) positively regulates cell proliferation, a key component of in-stent restenosis. (ahajournals.org)
  • Restenosis due to excessive intimal cell proliferation, which subsequently occurs in 20-50% of patients, represents one of the major clinical problems in contemporary cardiology, and no satisfactory method for its prevention has thus far been found. (semanticscholar.org)
  • Pathogen burden, inflammation, proliferation and apoptosis in human in-stent restenosis. (semanticscholar.org)
  • Quantitative coronary arteriography was performed at baseline, when clinically necessary, or routinely at 6 months following PCI. (acc.org)
  • Clinical, qualitative and quantitative angiographic variables were correlated with restenosis assessed as both a binary and a continuous variable. (onlinejacc.org)
  • 50% by quantitative coronary angiographic analysis in DES or within 5mm of the stent edges with signs of ischaemia. (elsevier.com)
  • Recently a few reports on prevention of restenosis in type 2 diabetic patients (T2DM) with the use of TZDs as been published. (centerwatch.com)
  • Prevention of coronary restenosis : the evolving evidence base for radiation therapy. (semanticscholar.org)
  • Future strategies for prevention of restenosis include modifications to the stent platform, the drug polymer or drug elution system, biocompatible stent coatings, use of bioresorbable scaffolds, and optimization of local and systemic anti-restenotic agents. (elsevier.com)
  • In this thesis, different modalities and treatment options for the treatment and prevention of coronary restenosis are discussed. (uu.nl)
  • As a result, the goal in prevention of in-stent restenosis is to develop drugs that are able to act both as insulin- and endothelium- sensitizers. (elsevier.com)
  • Use of first generation DES versus BMS (OR 0.35, 95% CI 0.31 to 0.39) and second generation DES versus first generation DES (OR 0.67, 95% CI 0.58 to 0.77) were independent predictors of lower rates of restenosis. (bmj.com)
  • To evaluate the effect of adding cilostazol to dual antiplatelet therapy (aspirin and thienopyridine) on rates of restenosis after coronary artery stenting. (york.ac.uk)
  • In both groups we compared the level in blood of CD45+ platelets, the clinical, laboratory and angiographic variables, which may affect the development of restenosis. (springermedizin.at)
  • In order to define the risk of the development of restenosis, we have built a logit regression model. (springermedizin.at)
  • Impaired insulin sensitivity and endothelial dysfunction are important markers in the development of restenosis after coronary stenting. (elsevier.com)
  • We sought to determine predictors of restenosis after coronary stenting (CS) in a consecutive series of patients. (onlinejacc.org)
  • The optimal treatment of in-stent restenosis (ISR) remains unknown. (bioportfolio.com)
  • Although a coronary stent implant is recognized to be a useful treatment for CAD ( 2 ), in-stent restenosis is still a significant clinical problem ( 3 ), and the restenosis rates in nondiabetic patients who receive stent implants are still 20-40% after 6 months ( 4 - 6 ). (diabetesjournals.org)
  • Objective To evaluate the long-term outcomes after different modalities of treatment of drug-eluting stent (DES) in-stent restenosis (ISR) in a 'real world' setting. (ovid.com)
  • For patients with multiple episodes of restenosis we believe this is an excellent treatment option. (beaumont.org)
  • MTAC considered that reductions in the number of cases of restenosis requiring medical treatment, readmission and repeat surgery would have future cost savings, if these effects were maintained in the long term. (cardiovascularnews.com)
  • of events P=0.001 11.1 This result suggests that trimetazidine treatment reduced stent restenosis by 62.2%, compared with control. (slideplayer.com)
  • Trimetazidine treatment has been shown to be a predictor of protection against stent restenosis after PCI. (slideplayer.com)
  • The biggest problem in the treatment of CHD is restenosis or re-narrowing of the coronary artery. (blogspot.co.uk)
  • I f you have time to read all of reference below this article, you will understand coronary stent and by-pass operation are not only option in CHD treatment. (blogspot.co.uk)
  • Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. (ccrjournal.org)
  • Alfonso F, Byrne R, Rivero F, Kastrati A. Current treatment of in-stent restenosis. (ccrjournal.org)
  • Giacoppo D, Gargiulo G, Aruta P, Capranzano P, Tamburino C, Capodanno D. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-ansalysis of 24 randomised trials and 4880 patients. (ccrjournal.org)
  • Repeat restenosis is often an indication for surgical treatment. (kardiologiapolska.pl)
  • Aims At present no proven standard treatment for drug-eluting stent (DES) restenosis is available, and the efficacy and safety of everolimus-eluting stent (EES) and zotarolimus-eluting stent (ZES) for DES restenosis are limited. (elsevier.com)
  • Because of the specific characteristics of the inflammatory response to different types of injury, different drugs and drug regimens for the treatment of restenosis may produce diverse effects. (scielo.br)
  • Platelets play an important role in restenosis by releasing one of these growth factors. (ahajournals.org)
  • Renin angiotensin system (RAS) plays an important role in restenosis by promoting neo-intimal hyperplasia. (ahajournals.org)